

## **HEALTH ANNUAL STATEMENT**

FOR THE YEAR ENDED DECEMBER 31, 2022 OF THE CONDITION AND AFFAIRS OF THE

# **Blue Care Network of Michigan**

NAIC	Group Code 0572		y Code <u>95610</u> Er	mployer's ID Number	38-2359234
Organized under the Laws of	(Current) Mic	(Prior) higan	, State of Domicile o	r Port of Entry	MI
Country of Domicile		United S	States of America		
Licensed as business type:		Health Main	tenance Organization		
Is HMO Federally Qualified?	Yes[]No[X]				
Incorporated/Organized	05/06/1981		Commenced Bu	usiness	05/13/1981
Statutory Home Office	20500 Civic Ce	nter Drive		Southfield	d, MI, US 48076
	(Street and N	lumber)		(City or Town, Stat	e, Country and Zip Code)
Main Administrative Office			ivic Center Drive t and Number)		
	Southfield, MI, US 48076				-799-6400
(City or	Town, State, Country and Zip	Code)		(Area Code) (	Telephone Number)
Mail Address	20500 Civic Center Drive (Street and Number or F		,		d, MI, US 48076 e, Country and Zip Code)
	,	•		(City of Town, Stat	e, Country and Zip Code)
Primary Location of Books and	d Records		Civic Center Drive t and Number)		
(City or	Southfield, MI, US 48076	Cada			-225-9095
, ,	Town, State, Country and Zip	•		(Area Code) (	Telephone Number)
Internet Website Address		www	.BCBSM.com		
Statutory Statement Contact	Kenn	eth A. Bluhm (Name)	·	(Area Co	313-225-9095 de) (Telephone Number)
	kbluhm@bcbsm.com	(Name)		800	-556-4348
	(E-mail Address)			(FA)	K Number)
Devision 1 0 Oktob		0	FFICERS		
President & Chief Executive Officer _	Kathryn Gala	ardi Levine	Tr	easurer	Waymond Eli Harris
Secretary _	Sheela Rac	Manyam		-	
			OTHER		
	_	DIRECTOR	S OR TRUSTEES		
	ne Angott	Willian	n Harrison Black		Kenneth Ray Dallafior
	nston Doyle yle Larsen		Holmon DNP, FNP-BC n Galardi Levine		Robert Paul Kelch MD Paula Jean Manderfield RN, JD
	ence Mozak In Weaver		d Earl Posthumus Alan Wolf D.O.		Gregory Alan Sudderth
Wai y 7 ti	III WCGVCI	Brace	Man Won D.C.		
State of	Michigan	SS			
County of	Oakland				
all of the herein described as statement, together with relate condition and affairs of the sa in accordance with the NAIC rules or regulations require respectively. Furthermore, th	sets were the absolute proper ed exhibits, schedules and expid id reporting entity as of the rep Annual Statement Instructions differences in reporting not r e scope of this attestation by t	ty of the said reporting of lanations therein contain orting period stated above and Accounting Practice elated to accounting problem described officers als	entity, free and clear fror ed, annexed or referred to e, and of its income and es and Procedures manu actices and procedures, o includes the related co	m any liens or claims on any liens or claims on a full and true state deductions therefrom full except to the extent according to the best presponding electronic	, and that on the reporting period stated above, hereon, except as herein stated, and that this ement of all the assets and liabilities and of the or the period ended, and have been completed that: (1) state law may differ; or, (2) that state it of their information, knowledge and belief, filling with the NAIC, when required, that is an ed by various regulators in lieu of or in addition
Kathryn Galardi		·-	nond Eli Harris		Sheela Rao Manyam
President & Chief Exe	ecutive Officer		Freasurer		Secretary
Subscribed and sworn to befo	re me this		b. If no, 1. State th 2. Date file	original filing?e amendment number.ed	 

# **ASSETS**

Sentes (Schende D)				Current Year		Prior Year
1. 1800 (SP-Centille D)			1 Assets	_		
2. Stores (Schedule D) 2.1 Preferent activate activate activated basis 2.2 Common stocks 3.2 Common stocks 3.2 Common stocks 3.3 Prefer toes 3.2 Common stocks 3.4 Preferent activates 4.1 Pregarders excepted by the company (text of several activates) 4.1 Pregarders excepted by the company (text of several activates) 4.2 Pregarders excepted by the company (text of several activates) 4.3 Procurement stock for the production of income (text of several activates) 5.	1.	Bonds (Schedule D)				
2.2 Professional stockes  2.3 Autragage learner on real trained (Schedule B)  3. First first risks  3. First first risks  3. First first risks  3. First first risks  4. Place cleated (Schedule A)  4. Place created (Schedule A)  4. Properties coussided by the company deed 5  onoranterances  4. Physicists held for the production of income gless  5. Contract risks  5. Schedule A, Place and Schedule A, Place			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
2.2 Common incides		` '			0	0
3. Most specifications on residentials (Schedule E).  3. First first literal						
3.3 First larms	3					
3.2 Cherr ham time liters. 4. Proporties cospined by the company glose \$ executions are company glose \$ executions \$ exec	0.	, ,			0	0
4. Propriets not for the production of income (less \$						
4.2 Proporties hed for the prostaction of income (less senanthemores)	4					
mounthornosis		,				
4.2 Properties held for the production of incomor (less \$ 0.000						0
\$ encurbrances)  4.3 Properties held for sale (leas 5 encurbrances)  5. Cash (\$		•				
4.3 Properties held for sale (less 8 encounterance)  5. Cash (\$					l	0
S. Clash (\$		•				
S. Cash (\$					0	0
(\$	5	,				
Investments (\$ 469, 967, 835   Schedule DA)   540, 214, 344   540, 214, 344   0   0   0   0   0   0   0   0   0	J.					
6. Contract losms, (including \$ premium notes)			540 214 344		540 214 344	602 410 121
7. Derharders (Schedule DB)	6					
8. Office invested assets (Schedule BA). 275, 989, 198		•				
9. Receivables for securities 10. Securities lending reinvested collateral assets (Schedule DL) 11. 249,884 11. 249,885 11. 249,877 11. 249,877 11. 34						
10. Securities lending reinvested collateral assets (Schedule DL)   11.249,884   11.249,884   3,856,754     11. Aggregate write-ins for invested assets   0.0   0   0   0   0     12. Subtotals, cash and invested assets (Lines to 11)   2.397,165,619   0   2.397,165,619   0   2.507,789,770     13. Title plants less \$   11.249,884   11.249,884   0   2.397,165,619   0   0   0     14. Investment income due and accrued   15,000,486   1						
11. Aggregate write-ins for invested assets (Lines 1 to 11)						
12 Subtotals, cash and invested assets (Lines 1 to 11)						
13. Title plants less \$						
Only		· · · · · · · · · · · · · · · · · · ·	2,007,100,010		2,007,100,010	
14. Investment income due and accrued   15,000,486   15		, , ,			0	0
15. Premiums and considerations:   15.1 Uncollected premiums and agents' balances in the course of collection   21,889,997		**				
15.1 Uncollected premiums and agents' balances in the course of collection 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$					10,000,100	
15.2 Defered premiums, agents' balances and installments booked but deferred and not yet due (including 5	10.		21 889 997	744 286	21 145 711	2 872 462
Determined and not yet due (including \$ = earned but unbilled premiums) \$ = 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0						
earned but unbilled premiums						
15.3 Accrued retrospective premiums (\$					l	0
Contracts subject to redetermination (\$ )   49,069,890   37,034,519		. ,				
16. Reinsurance:			49.069.890		49.069.890	37.034.519
16.1 Amounts recoverable from reinsurers	16.	•	-, -, -			, , , , ,
16.2 Funds held by or deposited with reinsured companies					0	0
16.3 Other amounts receivable under reinsurance contracts		16.2 Funds held by or deposited with reinsured companies			0	0
17. Amounts receivable relating to uninsured plans						
18.2 Net deferred tax asset	17.					
18.2 Net deferred tax asset	18.1	Current federal and foreign income tax recoverable and interest thereon	683		683	139 , 147
20. Electronic data processing equipment and software		=				
20. Electronic data processing equipment and software	19.	Guaranty funds receivable or on deposit			0	0
21. Furniture and equipment, including health care delivery assets (\$ ) 3,781,401   3,781,401   3,781,401   0	20.					
22. Net adjustment in assets and liabilities due to foreign exchange rates         0         0         0           23. Receivables from parent, subsidiaries and affiliates         59,048,963         59,048,963         66,260,911           24. Health care (\$ 95,406,139 ) and other amounts receivable         99,124,380         3,718,241         95,406,139         107,957,119           25. Aggregate write-ins for other than invested assets         0         0         0         7,003,578           26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)         2,681,410,632         8,243,928         2,673,166,704         2,791,906,983           27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts         0         0         0         0         0         0         0         0         2,791,906,983           28. Total (Lines 26 and 27)         2,681,410,632         8,243,928         2,673,166,704         2,791,906,983         2,791,906,983           1101.         50         50         50         50         50         60         0	21.	- ' '				
23. Receivables from parent, subsidiaries and affiliates		(\$)	3,781,401	3,781,401	0	0
23. Receivables from parent, subsidiaries and affiliates	22.					
25. Aggregate write-ins for other than invested assets       0       0       7,003,578         26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)       2,681,410,632       8,243,928       2,673,166,704       2,791,906,983         27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts       0       0       0         28. Total (Lines 26 and 27)       2,681,410,632       8,243,928       2,673,166,704       2,791,906,983         DETAILS OF WRITE-INS         1101.       1102.       1103.       1104.       1105.       1106.       1107.       1107.       1109.						
25. Aggregate write-ins for other than invested assets       0       0       7,003,578         26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)       2,681,410,632       8,243,928       2,673,166,704       2,791,906,983         27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts       0       0       0         28. Total (Lines 26 and 27)       2,681,410,632       8,243,928       2,673,166,704       2,791,906,983         DETAILS OF WRITE-INS         1101.       1102.       1103.       1104.       1105.       1106.       1107.       1107.       1109.	24.					
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)       2,681,410,632       8,243,928       2,673,166,704       2,791,906,983         27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts       0       0       0       0       0       0       2,791,906,983         28. Total (Lines 26 and 27)       2,681,410,632       8,243,928       2,673,166,704       2,791,906,983         1101.       1102.       1103.       1104.       1105.       1106.       1107.       1108.       1109. <td< td=""><td></td><td>·</td><td></td><td></td><td></td><td></td></td<>		·				
Protected Cell Accounts (Lines 12 to 25)	26.	Total assets excluding Separate Accounts, Segregated Accounts and				
Accounts		Protected Cell Accounts (Lines 12 to 25)	2,681,410,632	8,243,928	2,673,166,704	2,791,906,983
DETAILS OF WRITE-INS         1101.	27.				0	0
1101.	28.	Total (Lines 26 and 27)	2,681,410,632	8,243,928	2,673,166,704	2,791,906,983
1102.		DETAILS OF WRITE-INS				
1103	1101.					
1198. Summary of remaining write-ins for Line 11 from overflow page       .0 <td>1102.</td> <td></td> <td></td> <td></td> <td></td> <td></td>	1102.					
1199. Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)       0	1103.					
2501. Modified reinsurance experience adjustment	1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
2502.	1199.	·		_	0	0
2503.	2501.	Modified reinsurance experience adjustment			0	7,003,578
2503.	2502.				0	0
	2503.					
	2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0
	2599.					7,003,578

# **LIABILITIES, CAPITAL AND SURPLUS**

	LIABILITIES, CAP	IIAL AND	Current Year		Prior Year
	-	1	2	3	4
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$0 reinsurance ceded)		16,315,848		
2.	Accrued medical incentive pool and bonus amounts				
3.	Unpaid claims adjustment expenses				
4.	Aggregate health policy reserves, including the liability of			17,000,040	10,047,420
٦.	\$11,564,233 for medical loss ratio rebate per the Public				
	Health Service Act	48 541 373		48 541 373	100 323 001
5.	Aggregate life policy reserves	· · ·			0
	Property/casualty unearned premium reserves				0
6.	Aggregate health claim reserves				0
7.	Aggregate nealth claim reserves.				
8.					
9.	General expenses due or accrued	12,117,736		12,117,736	50, 133,486
10.1	Current federal and foreign income tax payable and interest thereon				0
	(including \$ on realized capital gains (losses))				
	Net deferred tax liability				0
11.	Ceded reinsurance premiums payable				
12.	Amounts withheld or retained for the account of others	·		· ·	
13.	Remittances and items not allocated	116,695		116,695	2,813
14.	Borrowed money (including \$ current) and				
	interest thereon \$				
	\$44,625 current)				
15.	Amounts due to parent, subsidiaries and affiliates	82,190,794		82,190,794	77,970,618
16.	Derivatives			0	0
17.	Payable for securities	18,381,865		18,381,865	22,325,471
18.	Payable for securities lending	11,249,884		11,249,884	8,856,754
19.	Funds held under reinsurance treaties (with \$				
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$ 0 certified reinsurers)			0	0
20.	Reinsurance in unauthorized and certified (\$				
20.	companies			0	0
21.	Net adjustments in assets and liabilities due to foreign exchange rates				
22.	Liability for amounts held under uninsured plans				
23.	Aggregate write-ins for other liabilities (including \$			44,440,270	20,041,400
23.	current)	5 017 222	0	5 017 222	7 401 400
0.4	Current)				
24.					
25.	Aggregate write-ins for special surplus funds				0
26.	Common capital stock				10,000
27.	Preferred capital stock				
28.	Gross paid in and contributed surplus				
29.	Surplus notes				
30.	Aggregate write-ins for other than special surplus funds				0
31.	Unassigned funds (surplus)	XXX	XXX	1,735,738,737	1,775,666,680
32.	Less treasury stock, at cost:				
	32.1 shares common (value included in Line 26				
	\$	XXX	XXX		
	32.2 shares preferred (value included in Line 27				
	\$	xxx	XXX		
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	1,751,451,782	1,791,379,725
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	2,673,166,704	2,791,906,983
	DETAILS OF WRITE-INS				
2301.	Escheats	5,017,322		5,017,322	7,401,408
2302.				0	0
2303.					
2398.	Summary of remaining write-ins for Line 23 from overflow page				
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	5,017,322	0	5,017,322	7,401,408
2501.	Totals (Lines 2501 tillu 2505 plus 2590)(Line 25 above)				0
2502.					
2503.	Summary of remaining write-ins for Line 25 from overflow page				
2598.	Table (11 and 0504 that 0500 at a 0500)(11 and 05 at a max				
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
3002.					
3003.					
3098.	Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX	0	0
3000	Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

# **STATEMENT OF REVENUE AND EXPENSES**

	STATEMENT OF REVENUE AN			Deina Vana
		Current 1	Year 2	Prior Year 3
		Uncovered	Total	Total
1. Member M	onths	XXX	7,961,550	8,092,569
<ol><li>Net premiu</li></ol>	m income ( including \$ non-health premium income)	XXX	4,151,192,419	3,911,401,546
3. Change in	unearned premium reserves and reserve for rate credits	XXX	(3,757,689)	12,403,026
4. Fee-for-ser	vice (net of \$ medical expenses)	XXX	0	0
5. Risk revenu	Je	xxx	0	0
6. Aggregate	write-ins for other health care related revenues	XXX	14,000	19,999
	write-ins for other non-health revenues			
	ues (Lines 2 to 7)			
	nd Medical:			0,020,021,071
	edical benefits	46.942.017	2.557.171.648	2.565.715.301
	ssional services			202,827,176
	errals			
			, ,	, ,
1	room and out-of-area			227,745,561
1	n drugs			442,825,204
	write-ins for other hospital and medical			
15. Incentive po	ool, withhold adjustments and bonus amounts		56,217,516	65,207,899
16. Subtotal (Li	nes 9 to 15)	167,657,018	3,636,886,462	3,594,620,481
Less:				
17. Net reinsur	ance recoveries		0	(61,244)
18. Total hospi	tal and medical (Lines 16 minus 17)	167,657,018	3,636,886,462	3,594,681,725
19. Non-health	claims (net)			
20. Claims adju	ustment expenses, including \$		163,860,419	148 , 161 , 884
-	ministrative expenses			
	reserves for life and accident and health contracts (including \$			
	, ,		(20, 160, 047)	(7 504 054)
	in reserves for life only)			
	writing deductions (Lines 18 through 22)			
	riting gain or (loss) (Lines 8 minus 23)			
	nent income earned (Exhibit of Net Investment Income, Line 17)			
26. Net realized	d capital gains (losses) less capital gains tax of \$		(53,885,564)	73,947,425
27. Net investn	nent gains (losses) (Lines 25 plus 26)	0	3,178,971	122,251,406
28. Net gain or	(loss) from agents' or premium balances charged off [(amount recovered			
\$	) (amount charged off \$			
29. Aggregate	write-ins for other income or expenses	0	649,571	0
	or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus			
	plus 29)	XXX	(35,618,038)	(98,053,070)
31. Federal and	d foreign income taxes incurred	xxx	561,214	42,007
32. Net income	(loss) (Lines 30 minus 31)	XXX	(36, 179, 252)	(98,095,077)
DETAILS (	DF WRITE-INS			
	nue	XXX	14,000	19,999
0602		XXX		
0603		XXX		
	f remaining write-ins for Line 6 from overflow page			0
_	es 0601 thru 0603 plus 0698)(Line 6 above)	XXX	14,000	19,999
,	3 000 1 0 000 pide 0000 / 2 000 0 0 0 0 0 0 0 0 0 0 0 0 0			· · · · · · · · · · · · · · · · · · ·
	f remaining write-ins for Line 7 from overflow page			0
	es 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
,	s or or till to troo plus or so (Line r above)		•	
	f remaining write-ins for Line 14 from overflow page		_	0
	es 1401 thru 1403 plus 1498)(Line 14 above)	0	0	00
		-		0
	ne		649,571	
	f compaigning units in a fact in a 20 from a conflour page		_	
	f remaining write-ins for Line 29 from overflow page			0
2999. Totals (Line	es 2901 thru 2903 plus 2998)(Line 29 above)	0	649,571	0

**STATEMENT OF REVENUE AND EXPENSES (Continued)** 

	STATEMENT OF REVENUE AND EXPENSES	Continuca	<i></i>
		Current Year	2 Prior Year
i	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	1 791 379 725	1 908 517 681
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves		
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$		
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax		
39.	Change in nonadmitted assets		(8,323,953
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles		
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus		
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)		
	45.3 Transferred from capital		
46.	Dividends to stockholders		
47.	Aggregate write-ins for gains or (losses) in surplus	0	0
48.	Net change in capital and surplus (Lines 34 to 47)		(117, 137, 957
49.	Capital and surplus end of reporting period (Line 33 plus 48)	1,751,451,782	1,791,379,725
43.		1,731,431,702	1,701,070,720
	DETAILS OF WRITE-INS		
4701.			
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page		0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

# **CASH FLOW**

	0/(01112011		
		1	2
		Current Year	Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance	4,080,088,023	3,964,490,049
2.	Net investment income	65,295,671	65,636,585
3.	Miscellaneous income	14,000	19,999
4.	Total (Lines 1 through 3)	4,145,397,694	4,030,146,633
5.	Benefit and loss related payments	3,589,516,671	3,628,721,170
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions	591,147,370	547,239,828
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$ tax on capital gains (losses)	422,750	(9,050)
10.	Total (Lines 5 through 9)	4,181,086,791	4,175,951,948
11.	Net cash from operations (Line 4 minus Line 10)	(35,689,097)	(145,805,315)
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds	1,145.889.586	2,403.688.604
	12.2 Stocks		
	12.3 Mortgage loans		0
	12.4 Real estate		0
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	, ,	
	12.7 Miscellaneous proceeds		13,427,886
	12.8 Total investment proceeds (Lines 12.1 to 12.7)		
13.	Cost of investments acquired (long-term only):	1,041,103,700	2,700,000,000
13.	13.1 Bonds	1 113 554 552	2 223 781 788
	13.2 Stocks		
	13.3 Mortgage loans	, ,	, ,
	13.4 Real estate		0
	13.5 Other invested assets		
			4,258,722
	13.6 Miscellaneous applications		
	13.7 Total investments acquired (Lines 13.1 to 13.6)		2,551,139,206
14.	Net increase (decrease) in contract loans and premium notes		0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(47,881,007)	239, 197, 428
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes		0
	16.2 Capital and paid in surplus, less treasury stock		
	16.3 Borrowed funds		0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		0
	16.5 Dividends to stockholders	0	0
	16.6 Other cash provided (applied)	21,374,328	(58,618,709)
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	21,374,328	(58,618,709)
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(62,195,776)	34,773,405
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year	602,410,120	567,636,716
	19.2 End of year (Line 18 plus Line 19.1)	540,214,344	602,410,120

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

# **ANALYSIS OF OPERATIONS BY LINES OF BUSINESS**

		<i>/</i> \	AVE I DID C		HONO D		OI DOSHILL				
		1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
			Comprehensive	Medicare	Dental	Vision	Health	XVIII	XIX		Other
		Total	(Hospital & Medical)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
	Net premium income	4, 151, 192, 419	2,820,783,876	28,481,267			116,653,251	1,185,274,025			
2.	rate credit	(3,757,689)	(3,757,689).	(15)				15			
3.	Fee-for-service (net of \$										
	medical expenses)	0									XXX
4.	Risk revenue	0									XXX
5.	Aggregate write-ins for other health care related revenues	14,000	14,000	0	0	0	0	0	0	0	XXX
6.	Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	XXX	xxx	xxx	xxx	XXX	xxx	C
7.	Total revenues (Lines 1 to 6)	4 . 147 . 448 . 730	2.817.040.187	28.481.252	0	0	116.653.251	1.185.274.040	0	0	0
8.	Hospital/medical benefits	2,557,171,648	1,592,979,620	17,252,726			87,628,403	859,310,899			XXX
9.	Other professional services	200,267,034	150.258.189	717.046			4.034.798	45,257,001			XXX
10.	Outside referrals	110.002.091	71.167.961	1,056,152			3.750.789	34.027.189			XXX
11.			168,912,421	1.029.939			8.599.499	56,425,978			XXX
12.	Prescription drugs	478,260,336	392,952,161	.,,,,			23,641,622	61.666.553			XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0	0		0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts.		35.545.074				992.653	19.679.789			XXX
15.	Subtotal (Lines 8 to 14)	3.636.886.462	2.411.815.426	20.055.863	0	0	128.647.764	1.076.367.409	0	0	XXX
_	Net reinsurance recoveries	0						,,,			XXX
17.	Total medical and hospital (Lines 15 minus 16)	3,636,886,462	2,411,815,426	20,055,863	0	0	128.647.764	1.076.367.409	0	0	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
19.	,	163,860,419		1.051.013			2,340,344	57,297,724			
20	General administrative expenses		320.981.088	3.221.019				90.133.414			
21.	Increase in reserves for accident and health contracts	(32.163.947)	(3,425,834)					(28,738,113)			XXX
22.	Increase in reserves for life contracts	0	XXXXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23.	Total underwriting deductions (Lines 17 to 22)	4,186,895,310	2,832,542,018	24.327.895		0		1.195.060.434			۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰
_	Total underwriting gain or (loss) (Line 7 minus Line 23)	(39,446,580)	(15,501,831)	4.153.357	۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰	0	(18,311,712)	(9,786,394)	٠٠		۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰
	DETAILS OF WRITE-INS			4, 100,007	u		(10,311,712)	(9,700,394)	0	0	0
0501.	Other revenue	14,000	14,000								XXX
0502.			-			.	.				XXX
0503.			-			.					XXX
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	xxx
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	14,000	14,000	0	0			0	0	0	XXX
0601.			XXX		XXX	XXX	XXX		XXX	XXX	
0602.			XXX	XXX	XXX	XXX		XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX		XXX	XXX	XXX	
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	xxx	xxx	xxx	XXX	xxx	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.	Totale (2mile 500 t mm 5000 pide 5000) (2mile 5 daste)										XXX
1302.											XXX
1303.											XXX
1398.		0	0	0	Λ	0	0	0	0	0	XXX
1300	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	۰	<sub>0</sub>	n		0	n	n		n	XXX
1399.	Totals (Lines 1301 tillu 1303 plus 1390) (Line 13 above)	U	0	U		1 0	U	U	U	ı	^^^

#### ~

## ANNUAL STATEMENT FOR THE YEAR 2022 OF THE Blue Care Network of Michigan

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 1 - PREMILIMS

	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical) individual	622,181,076		4,703,546	617,477,530
Comprehensive (hospital and medical) group	2,227,436,830		24,130,484	2,203,306,346
3. Medicare Supplement	28,481,267			28,481,267
4. Dental only				0
5. Vision only				0
6. Federal Employees Health Benefits Plan	116,653,251			116,653,251
7. Title XVIII - Medicare	1,190,471,122		5,197,097	1, 185, 274, 025
8. Title XIX - Medicaid	0			0
9. Credit A&H				0
10. Disability Income				0
11. Long-Term Care				0
12. Other health				0
13. Health subtotal (Lines 1 through 12)	4,185,223,546	0	34,031,127	4, 151, 192, 419
14. Life	0			0
15. Property/casualty	0			0
16. Totals (Lines 13 to 15)	4,185,223,546	0	34,031,127	4,151,192,419

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2 - CLAIMS INCURRED DURING THE YEAR

		1		hensive	4	5	6	7	8	9	10	11	12	13	14
				& Medical)											
			2	3	Medicare			Federal Employees Health	Title XVIII	Title XIX		Disability	Long-Term		Other
		Total	Individual	Group	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other Health	Non-Health
1.	Payments during the year:														
	1.1 Direct	3,524,287,870		1,831,873,242	20,210,836			128,869,184	1,073,013,494						
	1.2 Reinsurance assumed	0													
	1.3 Reinsurance ceded	0													
	1.4 Net	3,524,287,870	470,321,114	1,831,873,242	20,210,836	0	0	128,869,184	1,073,013,494	0	0	0	0	0	0
2.	Paid medical incentive pools and bonuses	65,068,635	8,462,804	27,081,096				2,141,478	27,383,257						
3.	Claim liability December 31, current year from Part 2A:														
	3.1 Direct	437,810,300	68,989,632	247,337,607	2,258,524	0	0	13,331,483	105,893,054	0	0	0	0	0	0
	3.2 Reinsurance assumed	0		0	0	0	0			0	0	0		0	
	3.3 Reinsurance ceded	0	0	0	0	0	0		•••••••••••••••••••••••••••••••••••••••		0	0		0	
	3.4 Net	437,810,300		247,337,607	2,258,524	0	0		105,893,054	n	0	٥		0	
4.	Claim reserve December 31, current year from Part 2D:			247,007,007	2,200,024			10,001,400	100,000,004						
	4.1 Direct	0													
	4.2 Reinsurance assumed														
	4.3 Reinsurance ceded	0													
	4.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5.	Accrued medical incentive pools and bonuses, current year	73,493,094	9,650,592	37,585,965				1,289,408	24,967,129						
6.	Net health care receivables (a)	(36,902,695)	(11,782,460)	(38,252,719)				2,824,836	10,307,648						
7.	Amounts recoverable from reinsurers December 31, current year	0													
8.	Claim liability December 31, prior year from Part 2A:														
	8.1 Direct	418.331.919	72,709,757	219.576.665	2 . 413 . 497	0	0	11.720.720	111.911.280	0				0	0
	8.2 Reinsurance assumed	0		210,010,000	0	0	0			0				0	0
	8.3 Reinsurance ceded				0	0	0			0				0	0
	8.4 Net	418,331,919		219.576.665	2,413,497	0	0		111.911.280	0	0	0	0	0	0
9.	Claim reserve December 31, prior year from Part 2D:	, ,		2.10,07.0,000			•					•			•
	9.1 Direct														
	9.2 Reinsurance assumed	0													
	9.3 Reinsurance ceded	0													
	9.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10.	Accrued medical incentive pools and bonuses, prior year	82,344,213	10,890,910	36,344,473				2,438,233	32,670,597						
11.	Amounts recoverable from reinsurers December 31, prior year	0													
	Incurred Benefits:	3,580,668,946	478,383,449	1.897.886.903	20,055,863	0	^	127,655,111	1,056,687,620	0	0	0	0	^	0
	12.1 Direct			, . , ,	20,055,863	0	0			]ū	0	0	0	0	0
	12.2 Reinsurance assumed	0 0	0	0		0	00		0	0	0	0 0		0	0
	12.3 Reinsurance ceded	3,580,668,946	478,383,449	•	U	0			1 056 007 000	0					0
	12.4 Net	3,380,008,946	478,383,449	1,897,886,903	20,055,863	U	0	127,655,111	1,056,687,620	0	0	0	0	0	U
13.	Incurred medical incentive pools and bonuses	56,217,516	7,222,486	28,322,588	0	0	0	992,653	19,679,789	0	0	0	0	0	0

<sup>(</sup>a) Excludes \$ ......160, 166 loans or advances to providers not yet expensed.

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

						LIADILII I EN	D OF CURREN	IIEAN					1	
	1	Compre		4	5	6	7	8	9	10	11	12	13	14
	]	(Hospital 8	,											
		2	3				Federal Employees							
				Medicare			Health	Title XVIII	Title XIX		Disability	Long-Term		Other
	Total	Individual	Group	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other Health	Non-Health
Reported in Process of Adjustment:			•			-								
,			50 054 400											
1.1 Direct	117,482,694	16,639,367	59,654,488	544,725			3,215,373	37,428,741						
1.2 Reinsurance assumed	0 .													
1.3 Reinsurance ceded	0													
1.4 Net					0	_	3,215,373	27 420 741	0	_	0	0	0	0
1.4 Net	117,402,094	10,039,307			0			37,420,741	U	0	U	0	0	
Incurred but Unreported:														
2.1 Direct	310 564 874	50 408 703	180 121 359	1 713 799			9 856 700	68.464.313						
2.2 Reinsurance assumed														
2.3 Reinsurance ceded	0  .													
2.4 Net	310 . 564 . 874	50.408.703	180 . 121 . 359	1.713.799	0	0	9,856,700	68,464,313	0	0	0	0	0	0
	, , ,	, , ,	, ,	, , , , ,			, , ,	, , , , ,						
<ol><li>Amounts Withheld from Paid Claims</li></ol>														
and Capitations:														
3.1 Direct	9,762,732	1,941,562	7,561,760				259,410							
3.2 Reinsurance assumed	0													
3.3 Reinsurance ceded														
3.4 Net	9,762,732	1,941,562	7,561,760	0	0	0	259,410	0	0	0	0	0	0	0
4. TOTALS:														
	407 040 000	00, 000, 000	047 007 007	0.050.504	^	_	10 001 100	105 000 054	^	0	_		_	
4.1 Direct		, , -	247,337,607	, - ,-			13,331,483	105,893,054			0	0	0	0
4.2 Reinsurance assumed	.   0  .			0	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4 Net	437,810,300	68,989,632	247,337,607	2,258,524	0		13,331,483	105,893,054	0	0	_	0	^	_
4.4 Net	437,010,300	00,505,032	241,001,001	2,200,024	U	U	10,001,460	100,090,004	U	U	U	U	U	U

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D		Claim Reserve ar December 31 o		5	6
	1	2	3	4		Estimated Claim Reserve and Claim
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Liability December 31 of Prior Year
Comprehensive (hospital and medical) individual	54,729,108	415,592,006	273,864	68,715,768	55,002,972	72,709,757
Comprehensive (hospital and medical) group	237,909,071	1,593,964,169	843,206	246,494,401	238,752,277	219,576,665
3. Medicare Supplement	2,360,565	17,850,271	2,713	2,255,811	2,363,278	2,413,497
4. Dental Only					0	0
5. Vision Only					0	0
6. Federal Employees Health Benefits Plan	10,336,457	118,532,728	35,913	13,295,570	10,372,370	11,720,720
7. Title XVIII - Medicare	99,709,240	973,304,255	108,851	105,784,203	99,818,091	111,911,280
8 Title XIX - Medicaid					0	0
9. Credit A&H					0	
10. Disability Income					0	
11. Long-Term Care					0	
12. Other health					0	0
13. Health subtotal (Lines 1 to 12)		3,119,243,429	1,264,547	436,545,753	406,308,988	418,331,919
14. Health care receivables (a)		98,964,214			0	135,866,909
15. Other non-health					0	0
16. Medical incentive pools and bonus amounts			10,541,736	62,951,358	75,610,371	82,344,213
17. Totals (Lines 13 - 14 + 15 + 16)	470,113,076	3,020,279,215	11,806,283	499,497,111	481,919,359	364,809,223

## **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		•	Cum	ulative Net Amounts P	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1.	Prior	256,818	258,605	258,796	258,799	258,802
2.	2018	2,082,873	2,408,232	2,411,458	2,411,464	2,411,467
3.	2019	XXX	2,223,147	2,545,858	2,548,491	2,548,203
4.	2020	XXX	XXX	2,071,254	2,435,327	2,437,167
5.	2021	XXX	XXX	XXX	2,122,778	2,449,403
6.	2022	XXX	XXX	XXX	XXX	2,009,556

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative N	et Amount Paid and Claim Outs	Liability, Claim Rese standing at End of Ye	erve and Medical Incentivar	ve Pool and Bonuses				
Year in Which Losses Were Incurred	1 2018	1 2 3 4 5							
		2019	2020	2021	2022				
1. Prior	259,368	258,605	258,796	258,800	258,802				
2. 2018	2,435,763	2,412,310	2,411,458	2,411,464	2,411,467				
3. 2019	XXX	2,575,064	2,549,959	2,548,491	2,548,203				
4. 2020	XXX	XXX	2,432,139	2,438,750	2,437,167				
5. 2021	XXX	XXX	XXX	2,458,876	2,453,493				
6. 2022	XXX	XXX	XXX	XXX	2,369,030				

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Prem	iums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2018		3,078,672	2,411,467	127,480	5.3	2,538,947	82.5			2,538,947	82.5
2. 2019		3.030.150	2.548.203	117.705	4.6	2.665.908	88.0			2.665.908	880
3. 2020		2.941.195	2.437.167	117.281	4.8	2,554,448	86.9			2.554.448	86.9
4. 2021		2,706,037	2,449,403	98,201	4.0	2,547,604	94.1	4,090	1,311	2,553,005	94.3
5. 2022		2,817,026	2,009,556	84,379	4.2	2,093,935	74.3	359,474	11,615	2,465,024	87.5

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Medicare Supplement

		Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022			
1.	Prior	2,897	2,892	2,890	2,887	2,886			
2.	2018	21,560	23,821	23,828	23,826	23,827			
3.	2019	XXX	21,014	23,226	23,221	23,216			
4.	2020	XXX	XXX		20,732	20,725			
5.	2021	XXX	XXX	XXX	17, 121	19,494			
6.	2022	XXX	XXX	XXX	XXX	17,850			

Section B - Incurred Health Claims - Medicare Supplement

	Sum of Cumulative Net	Amount Paid and Claim Outs	Liability, Claim Rese standing at End of Ye	rve and Medical Incention	ve Pool and Bonuses		
	1 2 3 4						
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022		
1. Prior		2,892	2,890	2,887	2,886		
2. 2018		23,823	23,828	23,826	23,827		
3. 2019	XXX	23,291	23,228	23,221	23,216		
4. 2020	XXX	XXX	20,904	20,737	20,725		
5. 2021	XXX	XXX	XXX	19,529	19,496		
6. 2022	XXX	XXX	XXX	XXX	20,106		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2018	34,904	23,827	1,781	7.5	25,608	73.4			25,608	73.4
2.	2019		23.216	1.711	7.4	24.927	74.0			24.927	74.0
3.	2020		20.725	1.467	7.1	22 . 192	71.3			22 .192	71.3
4.	2021	29,954	19,494		4.2	20,312	67.8	3	9	20,324	67.9
5.	2022	28,481	17,850	856	4.8	18,706	65.7	2,256	83	21,045	73.9

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

			Cur	mulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1.	Prior	8,863	8,994	8,999	8,999	8,999
2.	2018	94,615	104, 121	104,265	104,264	104,263
3.	2019	XXX	95 , 168	105,543	105,588	105,648
4.	2020	XXX	XXX	93,648	105,040	105,053
5.	2021	XXX	XXX	XXX	87,805	100,211
6.	2022	XXX	XXX	XXX	XXX	118,533

Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

			et Amount Paid and Clain Out:	n Liability, Claim Rese standing at End of Ye	erve and Medical Incention	ve Pool and Bonuses
	Year in Which Losses Were Incurred	1 2018	5 2022			
1.	Prior	8,959	8,994	8,999	8,999	8,999
2.	2018	105,431	104,272	104,265	104,264	104,263
3.	2019	XXX	105,499	105,700	105,588	105,648
4.	2020	XXX	XXX	104,912	105, 198	105,053
5.	2021	XXX	XXX	XXX	101,806	100,327
6.	2022	XXX	XXX	XXX	XXX	133,037

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2018	116,577	104,263	5,187	5.0	109,450	93.9			109,450	93.9
2.	2019	110 , 183	105,648	4,557	4.3	110,205	100.0			110,205	100.0
3.	2020	112,648	105,053	4,653	4.4	109,706	97.4			109,706	97.4
4.	2021	113.818	100.211	3.415	3.4	103.626	91.0	117	55	103.798	91.2
5	2022	116 653	118 533	1 940	1.6	120, 473	103.3	14 504	490	135 467	116 1

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

			Cun	nulative Net Amounts F	aid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1.	Prior	95,504	95,486	95,401	95,334	95,308
2.	2018	786, 173	904,924	903,927	904,079	904 , 189
3.	2019	XXX	818,564	933,749	932,298	932,953
4.	2020	XXX	XXX	777 , 131	884,033	884,891
5.	2021	XXX	XXX	XXX	915,440	1,040,937
6.	2022	XXX	XXX	XXX	XXX	973,304

#### Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net A		Liability, Claim Resetanding at End of Ye		ve Pool and Bonuses		
	1 2 3 4						
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022		
1. Prior	99,593	95,486	95,401	95,334	95,308		
2. 2018	902,114	905, 164	903,927	904,079	904, 189		
3. 2019	XXX	943,435	934,052	932,298	932,953		
4. 2020	XXX	XXX	901,890	901,433	884,891		
5. 2021	XXX	XXX	XXX	1,042,621	1,048,532		
6. 2022	XXX	XXX	XXX	XXX	1,096,568		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2018	1,008,986	904 , 189	40,166	4.4		93.6			944 , 355	93.6
2.	2019	1,078,315	932,953		3.6	966,541	89.6			966,541	89.6
3.	2020	1,009,483	884,891	35,774	4.0	920,665	91.2			920,665	91.2
4.	2021	1,073,995	1,040,937	42,056	4.0	1,082,993	100.8	7,596	434	1,091,023	101.6
5.	2022	1,185,274	973,304	47,412	4.9	1,020,716	86.1	123,264	3,893	1,147,873	96.8

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

			Cun	nulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1.	Prior	364,082	365,977	366,086		
2.	2018	2,985,221	3,441,098	3,443,478	3,443,633	3,443,746
3.	2019	XXX	3,157,893	3,608,376	3,609,598	3,610,020
4.	2020	XXX	XXX	2,960,865	3,445,132	3,447,836
5.	2021	XXX	XXX	XXX	3,143,144	3,610,045
6.	2022	XXX	XXX	XXX	XXX	3,119,243

#### Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net A	mount Paid and Claim Outs	Liability, Claim Rese standing at End of Yea	rve and Medical Incentions	ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior	370,821	365,977	366,086	366,020	365,995
2. 2018	3,467,192	3,445,569	3,443,478	3,443,633	3,443,746
3. 2019	XXX	3,647,289	3,612,939	3,609,598	3,610,020
4. 2020	XXX	XXX	3,459,845	3,466,118	3,447,836
5. 2021	XXX	XXX	XXX	3,622,832	3,621,848
6. 2022	XXX	XXX	XXX	XXX	3,618,741

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10	
						Claim and Claim				Total Claims and		
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment		
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)	
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent	
1.	2018	4,239,139	3,443,746	174,614	5.1	3,618,360	85.4	0	0	3,618,360	85.4	
2.	2019	4,252,346	3,610,020	157,561	4.4	3,767,581	88.6	0	0	3,767,581	88.6	
3.	2020	4,094,450	3,447,836	159, 175	4.6	3,607,011	88.1	0	0	3,607,011	88.1	
4.	2021	3,923,804	3,610,045	144,490	4.0	3,754,535	95.7	11,806	1,809	3,768,150	96.0	
5.	2022	4,147,434	3,119,243	134,587	4.3	3,253,830	78.5	499,498	16,081	3,769,409	90.9	

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

					SATE RESERVE	FOR ACCIDE	NT AND HEAL	TH CONTRACT						
		1	Comprel (Hospital &		4	5	6	7	8	9	10	11	12	13
			2 (Hospital e	3				Federal						
					Medicare			Employees Health	Title XVIII	Title XIX		Disability	Long-Term	
		Total	Individual	Group	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other
1.	Unearned premium reserves	2,285,500	1,459,480	825,450	380				190					
2.	Additional policy reserves (a)	0												
3.	Reserve for future contingent benefits	0												
4.	Reserve for rate credits or experience rating refunds													
	(including \$ for investment income)	11,564,233	11,456,831	107,402										
5.	Aggregate write-ins for other policy reserves	34,691,640	21,209,089	13,482,551	0	0	0	0	0	0	0	0	0	0
6.	Totals (gross)	48,541,373			380	0	0	0	190	0	0	0		0
7.	Reinsurance ceded	0												
8.	Totals (Net)(Page 3, Line 4)	48,541,373	34 , 125 , 400	14,415,403	380	0	0	0	190	0	0	0	0	0
9.	Present value of amounts not yet due on claims	0												
10.	Reserve for future contingent benefits													
11.	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0			0
12.	Totals (gross)	0	0	0	0	0								0
	Reinsurance ceded	0												
14.	Totals (Net)(Page 3, Line 7)	0	0	0		0	0	0	0	0	0	0	0	0
	DETAILS OF WRITE-INS													
0501.	ACA Risk adjustment	34,691,640	21,209,089	13,482,551										
0502.														
0503.														
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	34,691,640	21,209,089	13,482,551	0	0	0	0	0	0	0	0	0	0
1101.														
1102.														
1103.														
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes \$ \_\_\_\_\_ premium deficiency reserve.

## **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 3 - ANALYSIS OF EXPENSES

			YSIS OF EXPENSE			
		Claim Adjustme	ent Expenses 2	3	4	5
		Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$ for occupancy of					
	own building)	360,976	377,572	1,303,491	5,678	2,047,717
2.	Salary, wages and other benefits	45,636,164	47,732,765	164,614,784	2,792,586	260,776,299
3.	Commissions (less \$					
	ceded plus \$assumed)			86,801,843		86,801,843
4.	Legal fees and expenses	891,464	932,450	4,118,095	14,022	5,956,031
5.	Certifications and accreditation fees					0
6.	Auditing, actuarial and other consulting services	4,764,421	4,985,066	17,209,931	74,962	27,034,380
7.	Traveling expenses	418,421	437,658	1,510,926	6,581	2,373,586
8.	Marketing and advertising					
9.	Postage, express and telephone					
10.	Printing and office supplies					
11.	Occupancy, depreciation and amortization		·	3,581,979		
12.	Equipment					
13.	Cost or depreciation of EDP equipment and					
10.	software	10,236,132	10,706,754	36,962,902	161,002	58,066,790
14.	Outsourced services including EDP, claims, and other services	17 6/12 205	20 530 975	64 071 523	2 216 170	104 460 963
15.	Boards, bureaus and association fees					
	Insurance, except on real estate			1,807,920		
16.						
17.	Collection and bank service charges					
18.	Group service and administration fees					
19.	Reimbursements by uninsured plans					
20.	Reimbursements from fiscal intermediaries					
21.	Real estate expenses					
22.	Real estate taxes	157,281	164,512	567,945		889,738
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes			16,238,113		16,238,113
	23.2 State premium taxes					
	23.3 Regulatory authority licenses and fees			16,967,115		16,967,115
	23.4 Payroll taxes	2,413,324	2,524,280	8,714,565		13,652,169
	23.5 Other (excluding federal income and real estate taxes)					0
24.	Investment expenses not included elsewhere					0
25.	Aggregate write-ins for expenses	2,704	2,828	9,764	42	- ,
26.	Total expenses incurred (Lines 1 to 25)	79,073,668	84,786,751	418,312,376	7,728,741	(a)589,901,536
27.	Less expenses unpaid December 31, current year	8,632,958	9,256,690	12,117,736		30,007,384
28.	Add expenses unpaid December 31, prior year	8,495,159	8,352,269	50 , 133 , 486		66,980,914
29.	Amounts receivable relating to uninsured plans, prior year	8,409,629	8,099,158	31,271,020		47,779,807
30.	Amounts receivable relating to uninsured plans, current year	4,934,418	5,290,931	26,103,864		36,329,213
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	75,460,658	81,074,103	451,160,970	7,728,741	615,424,472
	DETAILS OF WRITE-INS					
2501.	Miscellaneous expenses	2,704	2,828	9,764	42	15,338
2502.						
2503.						
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25					

## **EXHIBIT OF NET INVESTMENT INCOME**

		1	2
		Collected During Year	
1.	U.S. government bonds	(a)8,624,553	9,226,299
1.1	Bonds exempt from U.S. tax		
1.2	Other bonds (unaffiliated)		
1.3	Bonds of affiliates		
2.1	Preferred stocks (unaffiliated)	(b)0	
2.11		(b)0	
2.2	Common stocks (unaffiliated)		
2.21	Common stocks of affiliates		
3.	Mortgage loans	(c)0	
4.	Real estate	(d) 0	
5	Contract Loans	0	0
6	Cash, cash equivalents and short-term investments		
7	Derivative instruments	(f)0	0
8.	Other invested assets	4,866,179	4,866,179
9.	Aggregate write-ins for investment income	77,274	77,274
10.	Total gross investment income	64,049,027	
11.	Investment expenses		(g)7,728,741
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)0
13.	Interest expense		(h)969,733
14.	Depreciation on real estate and other invested assets		(i)
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		8,698,474
17.	Net investment income (Line 10 minus Line 16)		57,064,535
	DETAILS OF WRITE-INS		
0901.	Security lending income	77,274	77,274
0902.			
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	77,274	77,274
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0
	ides \$3,004,141 accrual of discount less \$11,095,133 amortization of premium and less \$6,148,5	-	-
	ides \$ 0 accrual of discount less \$ 0 amortization of premium and less \$		
(c) Inclu	ides \$0 accrual of discount less \$0 amortization of premium and less \$	. 0 paid for accrued int	erest on purchases.

**EXHIBIT OF CAPITAL GAINS (LOSSES)** 

(g) Includes \$. ..

segregated and Separate Accounts.

		OF CAPI	IAL GAIN	3 (LUSSL	<u>.</u> 3)	
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity		(Columns 1 + 2)		Capital Gain (Loss)
1.	U.S. Government bonds	(9,441,301)	(36,350)	(9,477,651)	0	0
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)			(51,039,999)		
1.3	Bonds of affiliates	0	0		0	
2.1	Preferred stocks (unaffiliated)	0	0	0		
2.11	Preferred stocks of affiliates	0	0	0	0	
2.2	Common stocks (unaffiliated)	18,313,213	(12,399,752)	5,913,461	(30,895,521)	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans		0	0	0	0
4.	Real estate		0	0	0	0
5.	Contract loans	0	0	0	0	
6.	Cash, cash equivalents and short-term investments			(594,343)	(4,003)	0
7.	Derivative instruments				0	0
8.	Other invested assets				505,539	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	(6,902,885)	(46,982,679)	(53,885,564)	(30,318,259)	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0	0	0	C

# **EXHIBIT OF NON-ADMITTED ASSETS**

	EXHIBIT OF NON-ADMITTE	D ASSETS	2	3
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)			0
	Stocks (Schedule D):			
	2.1 Preferred stocks			0
	2.2 Common stocks			
3.	Mortgage loans on real estate (Schedule B):			
0.	3.1 First liens			0
	3.2 Other than first liens			
4.				
4.	Real estate (Schedule A): 4.1 Properties occupied by the company			0
	4.2 Properties held for the production of income.			
	4.3 Properties held for sale			
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			_
6	Contract loans			
6.				
7. o	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			
9.	Receivables for securities			
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection			
	$15.2\ Deferred\ premiums,\ agents'\ balances\ and\ installments\ booked\ but\ deferred\ and\ not\ yet\ due\$			0
	15.3 Accrued retrospective premiums and contracts subject to redetermination			0
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			
	16.2 Funds held by or deposited with reinsured companies			0
	16.3 Other amounts receivable under reinsurance contracts			0
17.	Amounts receivable relating to uninsured plans			0
18.1	Current federal and foreign income tax recoverable and interest thereon			0
18.2	Net deferred tax asset			0
19.	Guaranty funds receivable or on deposit			0
20.	Electronic data processing equipment and software		53,294	53,294
21.	Furniture and equipment, including health care delivery assets	3,781,401	6,734,678	2,953,277
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0
23.	Receivable from parent, subsidiaries and affiliates			
24.	Health care and other amounts receivable			
25.	Aggregate write-ins for other than invested assets			0
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			26,569,568
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			
28.	Total (Lines 26 and 27)	8,243,928	34,813,496	26,569,568
	DETAILS OF WRITE-INS			
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page			_
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Totals (Lines 1101 till till 1100 plas 1100)(Line 11 above)		0	
2502.				
2502. 2503.				
	Summary of remaining write-ins for Line 25 from overflow page		0	0
2598.				
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	0	0	0

## 17

# **EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY**

			Total Members at End of	_		6
	1	2	3	4	5	Current Year
Source of Enrollment	Prior Year	First Quarter	Second Quarter	Third Quarter	Current Year	Member Months
Health Maintenance Organizations		667,905		664,856	663,057	7,961,550
Provider Service Organizations						
Preferred Provider Organizations						
4. Point of Service						
5. Indemnity Only						
Aggregate write-ins for other lines of business	. 0	0	0	0	0	0
7. Total	669,179	667,905	663,820	664,856	663,057	7,961,550
DETAILS OF WRITE-INS						
0601.						
0602.						
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

#### NOTE 1 Summary of Significant Accounting Policies and Going Concern

#### A. Accounting Practices

The financial statements of Blue Care Network of Michigan (BCN) are presented on the basis of accounting practices required by the Michigan Department of Insurance and Financial Services (DIFS).

DIFS has adopted the National Association of Insurance Commissioner's (NAIC) Accounting Practices and Procedures Manual and the related NAIC Annual Statement Instructions (NAIC SAP) for determining and reporting the financial condition and results of operations of an insurance company. The Director of DIFS has the right to prescribe other specific practices that may deviate from NAIC practices and procedures. The accompanying statutory basis financial statements of BCN have been prepared in conformity with accounting practices prescribed by DIFS, including those related to SSAP No. 84 - Health Care and Government Insured Plan Receivables. DIFS implemented a prescribed practice for HMOs whereby loans or advances to hospitals or other providers under SSAP No. 84 are not permitted.

The prescribed practice had no impact on the net income for the periods ended December 31, 2022 and December 31, 2021. Without the prescribed practice, statutory surplus would have increased by \$160,166 and \$0 as of December 31, 2022 and December 31, 2021, respectively.

A reconciliation of the BCN's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of Michigan is shown below:

	SSAP#	F/S Page	F/S Line #	2022	2021
NET INCOME					
(1) State basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ (36,179,252)	\$ (98,095,077)
(2) State Prescribed Practices that are an increase/ (decrease) from NAIC SAP:					
(3) State Permitted Practices that are an increase/(decrease from NAIC SAP:	;)				
(4) NAIC SAP (1-2-3=4)	xxx	xxx	XXX	\$ (36,179,252)	\$ (98,095,077)
SURPLUS					
(5) State basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 1,751,451,782	\$ 1,791,379,725
(6) State Prescribed Practices that are an increase/(decreas	se) from NAIC S	SAP:			
Provider Advances	84	2	24	\$ (160,166)	\$ -
(7) State Permitted Practices that are an increase/(decrease	e) from NAIC SA	AP:			
(8) NAIC SAP (5-6-7=8)	xxx	xxx	xxx	\$ 1,751,611,948	\$ 1,791,379,725

#### B. Use of Estimates in the Preparation of the Financial Statements

The preparation of statutory-basis financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the statutory-basis financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates include assumptions used in amounts recorded relating to the Affordable Care Act (ACA); liabilities for unpaid claims, specifically incurred but not reported (IBNR); premium deficiency reserves and litigation-related contingencies.

#### C. Accounting Policy

Revenues – Premiums, which generally are billed in advance, are recognized as revenue during the respective periods of coverage. Premiums applicable to the unexpired portion of coverage are reflected in the accompanying statutory-basis statements of Admitted Assets, Liabilities, Capital and Surplus as Aggregate health policy reserves. Premiums received in advance of the billing due date are recorded as premiums received in advance.

Revenue from self-funded administrative services only (ASO) primarily consists of administrative fees for services provided, such as management of medical services, claims processing, and access to provider networks. Under ASO arrangements, self-funded groups retain the primary underwriting risk of paying claims. Amounts due from ASO groups are equal to the amounts required to pay claims and administrative fees. Administrative fees are earned as services are performed and are calculated based on the number of members in a group or the group's claim experience. Since benefit expenses for ASO arrangements are not the responsibility of BCN, claims paid by BCN and the corresponding receipt of claim payments are not reported in the accompanying Statement of Revenue and Expenses.

For the years ended December 31, 2022 and 2021, administrative fee revenues of \$50,804,947 and \$48,777,408, respectively, related to ASO arrangements are included as a reduction in general administrative expenses, cost containment expenses, and other claim adjustment expenses.

BCN follows the accounting policies below:

- (1) Cash Equivalents and Short-term investments include commercial paper, certificates of deposits, money market mutual funds and other readily marketable investments with initial maturities less than one year for short-term investments and three months or less for cash equivalents. In general, cash equivalents and short-term investments are recorded at amortized cost, which approximates market value. Money market mutual funds are recorded at fair value or net asset value (NAV) per share.
- (2) Bonds not backed by other loans that have a NAIC designation of one or two are stated at amortized cost using the scientific effective interest method. Bonds with a NAIC designation of three to six are carried at the lower of amortized cost or fair market value. BCN has not elected to use the Systematic approach for their SVO identified investments.
- (3) Common stocks stated at fair value. Changes in unrealized appreciation and depreciation in the value of common stocks are reflected as direct increases or decreases in surplus.
- (4) Preferred stocks
  - NOT APPLICABLE
- (5) Mortgage loans on real estate

NOT APPLICABLE

- (6) Loan-backed securities loan-backed securities with a NAIC designation of 1 or 2 are stated at amortized cost using the scientific effective interest method while those loan-backed securities with a NAIC designation of three or higher are carried at lower of amortized cost or fair market value. Premiums and discounts on loan-backed bonds and structured securities are amortized using the retrospective method based on anticipated prepayments at the date of purchase. Prepayment assumptions are obtained from broker- dealer survey values or internal estimates. Changes in estimated cash flows from the original purchase assumptions are accounted for using a prospective method. Should the present value of anticipated cash flows collected be less than the amortized cost basis, a determination will be made on whether the decline in value is other-than-temporary. If BCN has the ability and intent to hold the security to maturity, but does not expect recovery of the carrying value, the decline in value is recognized as an impairment loss.
- (7) Investments in subsidiaries, controlled and affiliated entities

NOT APPLICABLE

- (8) Investments in joint ventures, partnerships and limited liability companies BCN has ownership interests in partnerships and limited liability companies. BCN carries these investments based on the underlying U.S. GAAP equity of the investee. Such investments are included in the other invested assets line of the Assets page.
- (9) Derivatives

NOT APPLICABLE

- (10) Investment income in premium deficiency calculation BCN used anticipated investment income as part of the premium deficiency actuarial estimate calculation.
- (11) Claims unpaid The claims unpaid liability for incurred but unpaid and unreported claims is accrued in the period during which the services are provided and includes actuarial estimates of services performed that have not been reported to BCN by providers. Such estimates are based on historical claims experience modified for current trends and changes in benefits provided. Revisions in actuarial estimates are reported in the period in which they arise. BCN has reinsured certain components of its claims liabilities. Processing expense related to unpaid claims is accrued based on an estimate of cost to process such claims.
- (12) Fixed asset capitalization BCN had no change in its fixed asset capitalization policy from the prior period.
- (13) Pharmaceutical rebate receivables BCN receives pharmaceutical rebates from third-party pharmacy benefit managers. Rebate accruals are calculated using recent history of rebates received to develop an estimate
- D. Going Concern

Management has evaluated BCN's ability to continue as a going concern and does not have any substantial doubt about BCN's ability to continue as a going concern

#### NOTE 2 Accounting Changes and Corrections of Errors

NOT APPLICABLE

#### NOTE 3 Business Combinations and Goodwill

NOT APPLICABLE

#### NOTE 4 Discontinued Operations

NOT APPLICABLE

#### NOTE 5 Investments

Mortgage Loans, including Mezzanine Real Estate Loans

NOT APPLICABLE

Debt Restructuring

NOT APPLICABLE

Reverse Mortgages

NOT APPLICABLE

- Loan-Backed Securities
  - (1) Loan-backed securities designated highest-quality and high-quality (NAIC designations 1 and 2, respectively) are reported at amortized cost; securities that are designated medium quality, low quality, lowest quality and in or near default (NAIC designations 3 to 6, respectively) shall be reported at the lower of amortized cost or fair value. Premiums and discounts on loan-backed bonds and structured securities are amortized using the retrospective method based on anticipated prepayments at the date of purchase. Prepayment assumptions are obtained from broker-dealer survey values or internal estimates. Changes in estimated cash flows from the original purchase assumptions are accounted for using the prospective method.
  - (2) Other-Than-Temporary Impairment of Loan-Backed and Structured Securities

OTTI recognized 1st Quarter

a. Intent to sell
 b. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis

c. Total 1st Quarter (a+b)

OTTI recognized 2nd Quarter

d. Intent to sell

e. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis

f. Total 2nd Quarter (d+e)

OTTI recognized 3rd Quarter

g. Intent to sell

h. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis

i. Total 3rd Quarter (g+h)

OTTI recognized 4th Quarter

j. Intent to sell

k. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis

I. Total 4th Quarter (j+k)

m. Annual Aggregate Total (c+f+i+l)

1 mortized Cost Basis Before	2 Other-than- Temporary	3
Other-than-	mpairment	
Temporary	ecognized in	Fair Value
Impairment	Loss	1 - 2
\$ -	\$ -	\$ -
\$ -	\$ -	\$ -
\$ -	\$ -	\$ -
\$ -	\$ -	\$ -
\$ -	\$ -	\$ -
\$ -	\$ -	\$ -
\$ -	\$ -	\$ -
\$ -	\$ -	\$ _
\$ -	\$ -	\$ -
\$ -	\$ -	\$ -
\$ 49,267,573	\$ 5,751,804	\$ 43,515,769
\$ 49,267,573	\$ 5,751,804	\$ 43,515,769
	\$ 5,751,804	

<sup>(3)</sup> Other-Than-Temporary Impairment of Loan-Backed and Structured Securities by CUSIP - Not applicable

The table below reflects the loan-backed and structured securities impairment losses as of December 31, 2022. These securities were impaired on the basis that either the present value of the cash flows expected to be collected is less than the amortized cost basis or it is probable that the security will be sold before the recovery occurs.

1		2	3	4	5	6	7
CUSIP	4	Book/Adjusted Carrying Value Amortized Cost Before Current Period OTTI	 esent Value of ojected Cash Flows	Recognized Other-Than- Temporary Impairment	 Amortized Cost fter Other-Than- Temporary Impairment	Fair Value at time of OTTI	Date of Financial Statement Where Reported
3133KMSA4	\$	9,738,529	\$ 8,102,500	\$ 1,636,029	\$ 8,102,500	\$ 8,102,500	12/31/2022
3140LVTQ2	\$	4,197,533	\$ 3,423,339	\$ 774,194	\$ 3,423,339	\$ 3,423,339	12/31/2022
3140XCZL5	\$	4,368,776	\$ 3,752,876	\$ 615,901	\$ 3,752,876	\$ 3,752,876	12/31/2022
3133B9MG6	\$	5,712,438	\$ 5,224,671	\$ 487,768	\$ 5,224,671	\$ 5,224,671	12/31/2022
3140XF6W6	\$	4,990,330	\$ 4,335,461	\$ 654,869	\$ 4,335,461	\$ 4,335,461	12/31/2022
3133L8Y33	\$	3,786,690	\$ 3,429,006	\$ 357,684	\$ 3,429,006	\$ 3,429,006	12/31/2022
08163CBC2	\$	1,519,794	\$ 1,241,832	\$ 277,962	\$ 1,241,832	\$ 1,241,832	12/31/2022
05492JAW2	\$	1,287,661	\$ 1,062,938	\$ 224,723	\$ 1,062,938	\$ 1,062,938	12/31/2022
3132D6B58	\$	3,676,271	\$ 3,512,169	\$ 164,103	\$ 3,512,169	\$ 3,512,169	12/31/2022
3140FTKA8	\$	1,779,451	\$ 1,660,107	\$ 119,344	\$ 1,660,107	\$ 1,660,107	12/31/2022
87342RAH7	\$	489,890	\$ 397,189	\$ 92,700	\$ 397,189	\$ 397,189	12/31/2022
01627AAA6	\$	690,543	\$ 598,485	\$ 92,058	\$ 598,485	\$ 598,485	12/31/2022
74333HAC9	\$	499,982	\$ 426,330	\$ 73,652	\$ 426,330	\$ 426,330	12/31/2022
43732VAT3	\$	472,611	\$ 407,210	\$ 65,401	\$ 407,210	\$ 407,210	12/31/2022
3133BHKB1	\$	868,299	\$ 815,940	\$ 52,359	\$ 815,940	\$ 815,940	12/31/2022
12575AAE7	\$	194,671	\$ 164,540	\$ 30,131	\$ 164,540	\$ 164,540	12/31/2022
3133KP6B9	\$	2,604,610	\$ 2,579,160	\$ 25,451	\$ 2,579,160	\$ 2,579,160	12/31/2022
3133BPUN6	\$	2,389,493	\$ 2,382,018	\$ 7,474	\$ 2,382,018	\$ 2,382,018	12/31/2022
Total		XXX	XXX	\$ 5,751,804	XXX	XXX	XXX

(4) All impaired securities (fair value is less than cost or amortized cost) for which an other-than-temporary impairment has not been recognized in earnings as a realized loss (including securities with a recognized other-than-temporary impairment for non-interest related declines when a non-recognized interest related impairment remains):

a) The aggregate amount of unrealized losses:

1. Less than 12 Months	\$ (10,944,628)
2. 12 Months or Longer	\$ (22,945,397)
b)The aggregate related fair value of securities with unrealized losses:	
1. Less than 12 Months	\$ 186,696,921
2. 12 Months or Longer	\$ 120,333,033

(5) Because BCN has determined the investments, noted in (4)b above, have not been subject to credit losses and BCN does not have the intent to sell the securities and has the ability to hold such securities, BCN does not consider these investments to be other-than-temporarily impaired.

- E. Dollar Repurchase Agreements and/or Securities Lending Transactions
  - (1) Policy for Requiring Collateral or Other Security In the normal course of business, BCN participates in security lending agreements with a custodian bank. Under the agreement, BCN lends equity and bond securities in exchange for collateral, approximating at least 102% of the value of the securities loaned. Cash collateral is invested by the custodian bank in a money market fund and the offsetting collateral liability is included in Collateral from Lending activities. BCN's non-cash collateral is in the form of U.S. Treasury and U.S. agency securities. The security lending agreements are primarily overnight in nature and subject to renewal or termination. The fair value of the cash and non-cash collateral at December 31, 2022 is \$11,249,884 and \$2,078,591 respectively.
  - (2) Disclose the Carrying Amount and Classification of Both Assets and Liabilities BCN has no pledged assets under its security lending transaction
  - (3) Collateral Received
    - a. Aggregate Amount Collateral Received

	 Fair Value
1. Securities Lending	_
(a) Open	\$ 11,249,884
(b) 30 Days or Less	
(c) 31 to 60 Days	
(d) 61 to 90 Days	
(e) Greater Than 90 Days	
(f) Subtotal (a+b+c+d+e)	\$ 11,249,884
(g) Securities Received	
(h) Total Collateral Received (f+g)	\$ 11,249,884
2. Dollar Repurchase Agreement	
(a) Open	
(b) 30 Days or Less	
(c) 31 to 60 Days	
(d) 61 to 90 Days	
(e) Greater Than 90 Days	
(f) Subtotal (a+b+c+d+e)	\$ -
(g) Securities Received	
(h) Total Collateral Received (f+g)	\$ -
b. The fair value of that collateral and of the portion of that collateral that it has sold or	

repledged \$ 11,249,884

c. Information about Sources and Uses of Collateral – BCN receives cash and noncash collateral in an amount in excess of the fair value of the securities lent. BCN reinvests the cash collateral into a money market fund.

(4) Securities lending transactions administered by an affiliated agent

NOT APPLICABLE

(5) Collateral Reinvestment

a. Aggregate Amount Collateral Reinvested	Amortized Cost				
1. Securities Lending					
(a) Open	\$	11,249,884	\$	11,249,884	
(b) 30 Days or Less					
(c) 31 to 60 Days					
(d) 61 to 90 Days					
(e) 91 to 120 Days					
(f) 121 to 180 Days					
(g) 181 to 365 Days					
(h) 1 to 2 years					
(i) 2 to 3 years					
(j) Greater than 3 years					
(k) Subtotal (Sum of a through j)	\$	11,249,884	\$	11,249,884	
(I) Securities Received					
(m) Total Collateral Reinvested (k+l)	\$	11,249,884	\$	11,249,884	
2. Dollar Repurchase Agreement					
(a) Open					
(b) 30 Days or Less					
(c) 31 to 60 Days					
(d) 61 to 90 Days					
(e) 91 to 120 Days					
(f) 121 to 180 Days					
(g) 181 to 365 Days					
(h) 1 to 2 years					
(i) 2 to 3 years					
(j) Greater than 3 years					
(k) Subtotal (Sum of a through j)	\$	-	\$	-	
(I) Securities Received					
(m) Total Collateral Reinvested (k+l)	\$	-	\$	-	

b. Explanation of Additional Sources of Liquidity for Maturity Date Mismatches

NOT APPLICABLE

BCN has re-invested the cash collateral (Collateral to be returned) in a Money Market Mutual Fund with no specified maturity date and can be returned at any time.

- (6) Detail on Collateral Transactions Not Permitted by Contract or Custom to Sell or Repledge By contract, BCN through its custodian bank, is allowed to sell collateral received if borrowers are in default.
- (7) Collateral for securities lending transactions that extend beyond one year from the reporting date.

NOT APPLICABLE

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

NOT APPLICABLE

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

NOT APPLICABLE

H. Repurchase Agreements Transactions Accounted for as a Sale

NOT APPLICABLE

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

NOT APPLICABLE

J. Real Estate

NOT APPLICABLE

K. Low Income Housing tax Credits (LIHTC)

NOT APPLICABLE

L. Restricted Assets

Restricted Assets (Including Pledged) 2 3 4 5 6 7 Gross Total Gross (Admitted & (Admitted & Total Gross Non-Non-(Admitted & Total Total admitted) Admitted Non-admitted) Current Year Current Year Restricted to admitted) Restricted Restricted to Total from Restricted Increase/ Non-Admitted Total Current from Prior (Decrease) admitted Restricted Admitted Assets Restricted Asset Category Year Year (1 minus 2) Restricted (1 minus 4) (a) Assets (b) a. Subject to contractual obligation for which liability is not shown 0.000% 0.000% b. Collateral held under security lending agreements \$11,249,884 \$ 8,856,754 \$ 2,393,130 \$11,249,884 0.420% 0.421% c. Subject to repurchase agreements \$ 0.000% 0.000% d. Subject to reverse repurchase agreements \$ \$ 0.000% 0.000% e. Subject to dollar repurchase agreements \$ \$ 0.000% 0.000% f. Subject to dollar reverse repurchase

0.000%

0.000%

L. B	1	ı		i	١	i	ı	1		i	ı		
g. Placed under option contracts					\$	-			\$	-		0.000%	0.000%
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock					\$	_			\$	-		0.000%	0.000%
i. FHLB capital stock	\$ 3,97	3,400	\$ 4	4,205,500	\$	(232,100)			\$	3,973,400		0.148%	0.149%
j. On deposit with states	\$ 1,00	00,000	\$	1,000,000	\$	-			\$	1,000,000		0.037%	0.037%
k. On deposit with other regulatory bodies					\$	-			\$	-		0.000%	0.000%
Pledged collateral to FHLB (including assets backing funding agreements)	\$ 89,0	059,352	\$ 1	32,012,352	\$ (	42,953,000)			\$	89,059,352		3.321%	3.332%
m. Pledged as collateral not captured in other categories	\$	-			\$	_			\$	_		0.000%	0.000%
n. Other restricted assets	\$	200	\$	200	\$	-			\$	200		0.000%	0.000%
o Total Restricted Assets (Sum of a through n)	\$ 105.2	82 836	<b>\$</b> 1	46 074 806	\$ (	40 701 070)	\$	_	æ	105 282 836		3 926%	3 939%

<sup>(</sup>a) Column 1 divided by Asset Page, Column 1, Line 28

2. Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts That Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

NOT APPLICABLE

Detail of Other Restricted Assets (Contracts That Share Similar	Cha	racteristics	, Sı	uch as Rein	ısu	rance and De	eri	vatives, Are	Reported in the	e Aggregate)
	To	1 otal Gross		2		3		4	5 Gross	6
		dmitted & Non-		otal Gross					(Admitted & Non-	Admitted
		dmitted) estricted		Non- admitted)			ĺ	Total Current	admitted) Restricted	Restricted to
		from Current		Restricted rom Prior		Increase/ (Decrease)	ĺ	Year Admitted	to Total	Total Admitted
Description of Assets		Year		Year		(1 minus 2)	L	Restricted	Assets	Assets
BCBSM Foundation	\$	200	\$	200	\$	-	\$	200	0.000%	0.000%
Total (a)	\$	200	\$	200	\$	· -	\$	200	0.000%	0.000%

<sup>(</sup>a) Total Line for Columns 1 through 3 should equal 5L(1)n Columns 1 through 3 respectively and Total Line for Column 4 should equal 5L(1)n Column 5.

4. Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements										
		1		2	3 % of BACV to	4 % of BACV to				
Collateral Assets		ook/Adjusted carrying Value (BACV)		Fair Value	Total Assets (Admitted and Nonadmitted)*	Total Admitted Assets **				
a. Cash, Cash Equivalents and Short-Term Investments					0.000%	0.000%				
b. Schedule D, Part 1					0.000%	0.000%				
c. Schedule D, Part 2, Section 1					0.000%	0.000%				
d. Schedule D, Part 2, Section 2					0.000%	0.000%				
e. Schedule B					0.000%	0.000%				
f. Schedule A					0.000%	0.000%				
g. Schedule BA, Part 1					0.000%	0.000%				
h. Schedule DL, Part 1	\$	11,249,884	\$	11,249,884	0.420%	0.421%				
i. Other					0.000%	0.000%				
j. Total Collateral Assets (a+b+c+d+e+f+g+h+i)	\$	11,249,884	\$	11,249,884	0.420%	0.421%				

2 % of Liability to 1 Amount Total Liabilities \* 11,249,884 1.221%

Working Capital Finance Investments

NOT APPLICABLE

Offsetting and Netting of Assets and Liabilities

NOT APPLICABLE

O. 5GI Securities

NOT APPLICABLE

Short Sales

NOT APPLICABLE

Q. Prepayment Penalty and Acceleration Fees

General Account 78 2.012.008

1. Number of CUSIPs

2. Aggregate Amount of Investment Income

R. Reporting Entity's Share of Cash Pool by Asset Type

NOT APPLICABLE

NOTE 6 Joint Ventures, Partnerships and Limited Liability Companies

NOT APPLICABLE

<sup>(</sup>b) Column 5 divided by Asset Page, Column 3, Line 28

<sup>\*</sup> Column 1 divided by Asset Page, Line 26 (Column 1)

\*\* Column 1 divided by Asset Page, Line 26 (Column 3)

k. Recognized Obligation to Return Collateral Asset

<sup>\*</sup> Column 1 divided by Liability Page, Line 24 (Column 3)

#### NOTE 7 Investment Income

- A. BCN non-admits investment income due and accrued if the amounts are over 90 days past due.
- B. BCN admitted all accrued investment income as of December 31, 2022 and 2021.

#### NOTE 8 Derivative Instruments

**NOT APPLICABLE** 

#### NOTE 9 Income Taxes

#### A. Deferred Tax Assets/(Liabilities)

The income tax provision is calculated under the liability method. Deferred tax assets and liabilities are recorded based on the difference between the statutory financial statement and tax basis of assets and liabilities at the enacted rates. The net change in deferred tax assets and liabilities is applied directly to unassigned deficit. The nonadmitted portion of a net deferred tax asset is determined by applying the rules prescribed by Statement of Statutory Accounting Principles (SSAP) No. 101. Income Taxes.

1. The components of net deferred tax asset/(liability) at the end of the current period are as follows:

		12/31/2022			12/31/2021			Change	
	(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total
(a) Gross Deferred Tax Assets (b) Statutory Valuation Allowance Adjustment	Ordinary	Capital	\$ - \$ -	\$ 420,979 \$ 420,979	Capital	\$ 420,979 \$ 420,979	\$ (420,979) \$ (420,979)	\$ -	\$ (420,979) \$ (420,979)
(c) Adjusted Gross Deferred Tax Assets (1a - 1b)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
(d) Deferred Tax Assets Nonadmitted (e) Subtotal Net Admitted Deferred Tax Asset			\$ -			\$ -	\$ -	\$ -	\$ -
(1c - 1d) (f) Deferred Tax Liabilities	\$ -	\$ -	\$ - \$ -	\$ -	\$ -	\$ - \$ -	\$ - \$ -	\$ - \$ -	\$ - \$ -
(g) Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -

2. Admission Calculation Components SSAP No. 101:

Admission Calculation Components SSA	AP NO. 101.									
		12/31/2022			12/31/2021		Change			
	(1)	(2)	(3) (Col. 1 + 2)	(4)	(5)	(6) (Col. 4 + 5)	(7) (Col. 1 - 4)	(8) (Col. 2 - 5)	(9) (Col. 7 + 8)	
	Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total	
(a) Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks			\$ -			\$ -	\$ -	\$ -	\$ -	
(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)			\$ -			\$ -	\$ -	\$ -	\$ -	
Adjusted Gross Deferred Tax     Assets Expected to be Realized     Following the Balance Sheet Date.			\$ -			\$ -	\$ -	\$ -	\$ -	
Adjusted Gross Deferred Tax     Assets Allowed per Limitation     Threshold.	xxx	xxx		xxx	xxx		xxx	xxx	\$ -	
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.			\$ -			\$ -	\$ -	\$ -	\$ -	
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	\$ -	\$ -	\$ -	\$ -	<b>S</b> -	s -	<b>S</b> -	<b>.</b> .	<b> </b>   <b>s</b> -	

Under the Federal Internal Revenue Code, ordinary losses can be carried back two years for entities taxed as nonlife insurance companies, while capital losses for entities taxed both as nonlife and life insurance companies can be carried back three years. For losses arising in tax years after 2017, entities taxed as life insurance companies are not permitted to carryback ordinary losses.

3.	Other Admissibility Criteria
٠.	

a. Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.

b. Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.

5 2022 2021

0.000%

5 -

#### 4. Impact of Tax Planning Strategies

(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.

	12/31/2022		12/31	/2021	Cha	ange
	(1)	(2)	(3)	(4)	(5) (Col. 1 - 3)	(6) (Col. 2 - 4)
	Ordinary	Capital	Ordinary	Capital	`Ordinary ´	` Capital ´
Adjusted Gross DTAs amount from Note 9A1     (c)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies					0.000%	0.000%
Net Admitted Adjusted Gross DTAs amount from Note 9A1(e)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies					0.000%	0.000%

b. Does the Company's tax-planning strategies include the use of reinsurance?

Yes [ ] No [X]

B. Unrecognized Deferred Tax Liabilities

NOT APPLICABLE

C. Components of Income Tax Incurred

BCN has identified specific investment activity subject to tax as unrelated debt-financed income associated with the Federal Home Loan Bank loan proceeds, offset by applicable expenses and charitable contribution deductions.

BCN has been recognized by the Internal Revenue Service, under Internal Revenue Code Section 501(c)(4), as an organization exempt from tax under Section 501 (a). BCN incurs unrelated business income that generates federal income taxes. There were no material uncertain tax positions as of December 31, 2022 or 2021.

			(4)		(2)		(3) (Col. 1 - 2)
1.	Current Income Tax	1	(1) 2/31/2022	,	12/31/2021		(Col. 1 - 2) Change
	(a) Federal	\$	561,214	\$	22,755	\$	538,459
	(b) Foreign					\$	-
	(c) Subtotal (1a+1b)	\$	561,214	\$	22,755	\$	538,459
	(d) Federal income tax on net capital gains			\$	19,252	\$	(19,252)
	(e) Utilization of capital loss carry-forwards (f) Other	œ.	160,347	œ	23,198	\$ \$	137,149
	(g) Federal and foreign income taxes incurred (1c+1d+1e+1f)	\$ \$	721,561	\$ \$	65,205	\$	656,356
	(g) I dadia and foreign mounte taxed mounted (10 · 10 · 11)	ľ	721,001	Ψ	00,200	۳	000,000
2.	Deferred Tax Assets:						
	(a) Ordinary:						
	(1) Discounting of unpaid losses					\$	-
	(2) Unearned premium reserve					\$	-
	(3) Policyholder reserves					\$	-
	(4) Investments					\$	-
	<ul><li>(5) Deferred acquisition costs</li><li>(6) Policyholder dividends accrual</li></ul>					\$ \$	-
	(7) Fixed assets					\$	-
	(8) Compensation and benefits accrual					\$	_
	(9) Pension accrual					\$	_
	(10) Receivables - nonadmitted					\$	-
	(11) Net operating loss carry-forward					\$	-
	(12) Tax credit carry-forward					\$	-
	(13) Other			\$	420,979	\$	(420,979)
	(99) Subtotal (sum of 2a1 through 2a13)	\$	-	\$	420,979	\$	(420,979)
	(b) Statutory valuation allowance adjustment			\$	420,979	\$	(420,979)
	(c) Nonadmitted			_		\$	-
	(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	\$	-	\$	-	\$	-
	(e) Capital: (1) Investments					\$	
	(2) Net capital loss carry-forward					\$	_
	(3) Real estate					\$	_
	(4) Other					\$	_
	(99) Subtotal (2e1+2e2+2e3+2e4)	\$	-	\$	-	\$	-
	(f) Statutory valuation allowance adjustment					\$	-
	(g) Nonadmitted					\$	-
	(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	\$	-	\$	-	\$	-
	(i) Admitted deferred tax assets (2d + 2h)	\$	-	\$	-	\$	-
3.	Deferred Tax Liabilities:						
٥.	(a) Ordinary:						
	(1) Investments					\$	_
	(2) Fixed assets					\$	_
	(3) Deferred and uncollected premium					\$	-
	(4) Policyholder reserves					\$	-
	(5) Other					\$	-
	(99) Subtotal (3a1+3a2+3a3+3a4+3a5)	\$	-	\$	-	\$	-
	(b) Capital:						
	(1) Investments					\$	-
	(2) Real estate					\$	-
	(3) Other (00) Subtotal (3h1+3h3+3h3)	æ		œ		\$	-
	(99) Subtotal (3b1+3b2+3b3) (c) Deferred tax liabilities (3a99 + 3b99)	\$ \$	-	\$ \$	<del>-</del>	\$ \$	-
<u>4</u> I	Net deferred tax assets/liabilities (2i - 3c)	\$	-	\$	-	Ф \$	-
→. I	vot deletted tax assets/liabilities (21 - 50)	Ψ	-	Ψ		Ψ	

D. Significant book to tax adjustments – During 2022, BCN incurred realized net capital gains of \$0. A valuation allowance against contribution carry overs of \$0 and \$420,979 has been recorded at December 31, 2022 and 2021 respectively.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, implemented a 15% minimum tax on book income of certain large corporations, a 1% excise tax on net stock repurchases and several tax incentives to promote clean energy. Based upon our current analysis of the provisions, we do not believe this legislation will have a material impact on our financial statements.

- E. Loss carry-forwards, credit carry-forwards As of December 31, 2022, BCN had no operating loss or tax credit carry-forward.
- F. Consolidated Tax Filing

NOT APPLICABLE

G. Loss Contingencies

NOT APPLICABLE - BCN believes that any income tax liability for uncertain tax positions will not significantly increase or decrease within the next twelve months.

H. Repatriation Transition Tax (RTT)

NOT APPLICABLE

I. Alternative Minimum Tax (AMT) Credit

NOT APPLICABLE

#### NOTE 10 Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

- A. On a routine basis, BCN conducts business transactions with its parent, Blue Cross Blue Shield of Michigan Mutual Insurance Company (BCBSM), and affiliates: Woodward Straits Insurance Company (WSIC), a subsidiary of BCBSM; Advantasure, Inc., Tessellate Holdings, LLC and COBX CO, each a wholly owned subsidiary of Emergent Holdings, Inc. (EHI), a subsidiary of BCBSM; Accident Fund Insurance Company of America (AFICA), a subsidiary of Accident Fund Holdings, Inc. (AFHI), a subsidiary of EHI.; Bricktown Capital, LLC a wholly owned subsidiary of Financial Services Holding Company, LLC, a subsidiary of BCBSM; and LifeSecure Insurance Co. a wholly owned subsidiary of LifeSecure Holdings Corporation, a subsidiary of BCBSM.
- B. Transactions with BCBSM include payments for health benefit coverage; processing and payment of certain claims; underpayments and/or overpayments due to and from hospitals; management, administrative and professional services; allocated employee salaries and related benefits; building rent; purchased services including agent fees; and reinsurance. Transactions with affiliates include management, administrative and professional services; workers' compensation coverage; malpractice liability coverage; insolvency coverage; and investment management.

Administrative support fees incurred from BCBSM were allocated to the statutory administrative expense categories of cost containment, other claims adjustment, general administrative and investment expenses, based on BCBSM's statutory administrative expense categories. These statutory administrative expense categories were further allocated to detailed expense accounts based on the BCBSM's expense detail.

On October 31, 2022, BCN purchased an affiliated surplus note for \$8,250,000 from AFHI, with an August 1, 2032 maturity date and recorded as part of other invested assets in the statements of admitted assets, liabilities, capital and surplus. Interest at 8.5% per annum shall be recognized upon approval from DIFS. Repayment of principal and interest on the note is restricted to earned surplus of AFHI and all such payments must be approved by DIFS. BCN account for the investment under guidance from SSAP No. 97, Investments in Subsidiary, Controlled and Affiliated Entities, SSAP No. 41R, Surplus Notes, and SSAP No. 26, Bonds, Excluding Loan-Backed and Structured Securities.

For the years ended December 31, 2022 and 2021, \$771,993,155 and \$1,516,547,824, respectively, were billed from BCBSM and affiliates for the operating activities detailed above. The majority of these transactions were related to BCBSM.

For the years ended December 31, 2022 and 2021, \$376,714,901 and \$89,320,553, respectively, were billed to BCBSM and affiliates for the operating activities detailed above. The majority of these transactions were related to BCBSM.

C. Transactions with related party who are not reported on Schedule Y

**NOT APPLICABLE** 

D. Except for reinsurance ceded and ceded reinsurance premiums payable, all related-party receivable and payable balances are classified as either claims unpaid or amounts due to or receivables from parent, subsidiaries, and affiliates.

As of December 31, 2022 and 2021, BCN had \$59,048,963 and \$73,264,488, respectively, in related party receivables. The majority of these balances were related to BCBSM

As of December 31, 2022 and 2021, BCN had \$82,190,794 and \$104,627,803, respectively, in related party payables. The majority of these balances were related to BCRSM

- E. BCN has agreements with BCBSM and affiliates under which the parties may provide services to or receive services from BCN. Unless otherwise required under IRC guidelines, the agreements provide for monthly payments and a year-end settlement based on the actual cost of services performed.
- F. Affiliate Guarantees

NOT APPLICABLE

- G. All outstanding shares of BCN are owned by BCBSM.
- H. Ownership in upstream affiliate or parent

NOT APPLICABLE

I. Investment in SCA

NOT APPLICABLE

J. Investment Impaired

NOT APPLICABLE

K. Investment in a foreign insurance subsidiary

NOT APPLICABLE

L. Investment in downstream noninsurance holding company

NOT APPLICABLE

M. All SCA Investments

NOT APPLICABLE

N. Investment in Insurance SCAs

NOT APPLICABLE

O. SCA or SSAP 48 Entity Loss Tracking

NOT APPLICABLE

#### NOTE 11 Debt

A. Debt Including Capital Notes

NOT APPLICABLE

- B. FHLB (Federal Home Loan Bank) Agreements
  - (1) BCN became a member of the Federal Home Loan Bank of Indianapolis (FHLBI) on December 1, 2009, in order to obtain short-term, long-term and line-of-credit borrowing privileges. As of December 31, 2022, BCN has \$50,000,000 outstanding at a rate of 1.89% with a maturity of November 8, 2024. BCN plans to utilize any funding obtained to cover operational needs or longer-term strategy plans. Borrowings are accounted for consistent with SSAP No. 15, Debt and Holding Company Obligations. The loans are collateralized by government securities at 105% of the outstanding loan balance. BCN calculates the actual or estimated borrowing capacity based on current FHLBI capital Stock.

(2)	FHLB	Capital	Stock
-----	------	---------	-------

<ul> <li>a. Aggregate Tot</li> </ul>	als
--------------------------------------	-----

39.39.10	Total
1. Current Year	
(a) Membership Stock - Class A	
(b) Membership Stock - Class B	\$ 3,973,400
(c) Activity Stock	
(d) Excess Stock	
(e) Aggregate Total (a+b+c+d)	\$ 3,973,400
(f) Actual or estimated Borrowing Capacity as Determined by the Insurer	\$ 88,297,778
2. Prior Year-end	
(a) Membership Stock - Class A	
(b) Membership Stock - Class B	\$ 4,205,500
(c) Activity Stock	
(d) Excess Stock	
(e) Aggregate Total (a+b+c+d)	\$ 4,205,500
(f) Actual or estimated Borrowing Capacity as Determined by the Insurer	\$ 93,455,556

<sup>11</sup>B(2)a1(f) should be equal to or greater than 11B(4)a1(d) 11B(2)a2(f) should be equal to or greater than 11B(4)a2(d)

b. Membership Stock (Class A and B) Eligible and Not Eligible for Redemption

			Eligible for Redemption							
	1	2	3	4	5	6				
	Current Year Total (2+3+4+5+6)	Not Eligible for Redemption	Less Than 6 Months	6 Months to Less Than 1 Year	1 to Less Than 3 Years	3 to 5 Years				
Membership Stock					· -					

1. Class A 2. Class B 3,973,400 3,973,400

11B(2)b1 Current Year Total (Column 1) should equal 11B(2)a1(a) Total (Column 1) 11B(2)b2 Current Year Total (Column 1) should equal 11B(2)a1(b) Total (Column 1)

#### (3) Collateral Pledged to FHLB

a. Amount Pledged as of Reporting Date

	1	2		3
			Αç	ggregate Total
	 Fair Value	 Carrying Value		Borrowing
Current Year Total Collateral Pledged	\$ 92,662,330	\$ 89,059,353	\$	50,000,000
2. Prior Year-end Total Collateral Pledged	\$ 137,439,848	\$ 132,084,729	\$	50,000,000

 $11B(3)a1 \ (Columns\ 1,\ 2\ and\ 3)\ should\ be\ equal\ to\ or\ less\ than\ 11B(3)b1\ (Columns\ 1,\ 2\ and\ 3\ respectively)$ 

11B(3)a2 (Columns 1, 2 and 3) should be equal to or less than 11B(3)b2 (Columns 1, 2 and 3 respectively) 11B(3)a3 (Columns 1, 2 and 3) should be equal to or less than 11B(3)b3 (Columns 1, 2 and 3 respectively)

11B(3)a4 (Columns 1, 2 and 3) should be equal to or less than 11B(3)b4 (Columns 1, 2 and 3 respectively)

b. Maximum Amount Pledged During Reporting Period

2 Amount Borrowed at Time of Maximum Carrying Value Collateral 1. Current Year Total Maximum Collateral Pledged 129.461.627 \$ 124.376.087 50.000.000 \$ 2. Prior Year-end Total Maximum Collateral Pledged 160.675.765 50.000.000 154.252.026 \$

# (4) Borrowing from FHLB

a. Amount as of Reporting Date

		Funding Agreements Reserves
	 Total	Established
1. Current Year		
(a) Debt		XXX
(b) Funding Agreements	\$ 50,000,000	
(c) Other		XXX
(d) Aggregate Total (a+b+c)	\$ 50,000,000	\$ -
2. Prior Year end		
(a) Debt		XXX
(b) Funding Agreements	\$ 50,000,000	
(c) Other		XXX
(d) Aggregate Total (a+b+c)	\$ 50,000,000	\$ -
. Maximum Amount During Reporting Period (Current Year)		
	Total	
1 Dobt		

		Total
1. Debt	-	
2. Funding Agreements	\$	50,000,000
3. Other		
4. Aggregate Total (Lines 1+2+3)	\$	50,000,000

<sup>11</sup>B(4)b4 (Columns 1, 2 and 3) should be equal to or greater than 11B(4)a1(d) (Columns 1, 2 and 3 respectively)

c. FHLB - Prepayment Obligations

Does the company have prepayment obligations under the following arrangements (YES/NO)?

No

1. Debt

2. Funding Agreements No 3. Other No

# NOTE 12 Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

NOT APPLICABLE

B. Plan Asset Investment Policies and Procedures

NOT APPLICABLE

C. The fair value of each class of plan assets

NOT APPLICABLE

D. Basis of Rate-of-Return-on-Assets Assumption

NOT APPLICABLE

E. Defined Contribution Plan

NOT APPLICABLE

F. Multiemployer Plans

NOT APPLICABLE

G. Consolidated/Holding Company Plans

BCBSM has the responsibility for administering and funding the pension and other postretirement benefits for BCN, including qualified and non-qualified noncontributory defined benefit pension plans, and qualified defined contribution and deferred compensation plans. BCN has no legal obligation for benefits under these plans. BCBSM allocates expenses to BCN based on allocations supporting other employment and overhead costs. BCN's share of net expense for qualified and non-qualified pension plans, other postretirement benefit plans and qualified defined contribution plans was:

 Qualified and non-qualified pensions plans
 2022
 2021

 Qualified and non-qualified pensions plans
 \$14,108,613
 \$17,147,805

 Other postretirement benefit plans
 (2,618,097)
 (2,937,927)

 Qualified defined contribution plan
 6,778,697
 6,938,870

The above expenses and amounts due to BCBSM related to the retirement expenses, as of December 31, 2022 and 2021, are included in the amounts disclosed in Note 10.

H. Postemployment Benefits and Compensated Absences

NOT APPLICABLE

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

NOT APPLICABLE

#### NOTE 13 Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

- A. BCN has 500 shares of common stock authorized; and 100 shares issued and outstanding. All shares are one class and have a par value of \$100 per share.
- B. Preferred stock

NOT APPLICABLE

- C. Dividend restrictions BCN's Articles of Incorporation prohibit dividends.
- D. Dividends paid

NOT APPLICABLE

E. Stockholder's portion of ordinary dividends

NOT APPLICABLE

F. Restrictions placed on unassigned funds (surplus)

NOT APPLICABLE

G. The total amount of advances to surplus not repaid

NOT APPLICABLE

H. The amount of stock held by BCN for special purposes

NOT APPLICABLE

I. Special surplus fund changes

NOT APPLICABLE

- J. The portion of unassigned funds (surplus) represented or reduced by cumulative unrealized gains and losses was a net unrealized gain of \$40.492.262 at December 31, 2022.
- K. Surplus notes

NOT APPLICABLE

L. Impact of any restatement due to quasi-reorganization

NOT APPLICABLE

M. Effective date(s) of all quasi-reorganizations in the prior 10 years is/are

NOT APPLICABLE

#### NOTE 14 Liabilities, Contingencies and Assessments

A. Contingent Commitments

BCN has outstanding commitments for additional investments to its joint ventures and partnership interests in the amount of \$71,001,150 at December 31, 2022.

R Assessments

The following items were recognized under SSAP No. 35R, Guaranty Fund and Other Assessments:

Effective October 1, 2018, the State of Michigan enacted the Insurance Provider Assessment (IPA). The IPA is a fixed-rate tax based on per member per month membership assessed on health insurers authorized to deliver, issue for delivery, or renew a policy in the state of Michigan (including HMOs). The liability is reflected in general expenses due or accrued as of December 31, 2022 and 2021, in the amount of \$8,038,883 and \$8,728,859, respectively.

Effective October 1, 2012, through September 30, 2029, the Affordable Care Act (ACA) requires a comparative effectiveness assessment to fund health outcome and clinical effectiveness research conducted by the Patient Centered Outcomes Research Institute, a non-profit organization created by the ACA. The liability is reflected in general expenses due or accrued as of December 31, 2022 and 2021, in the amount of \$1,663,482 and \$1,719,754, respectively.

C. Gain Contingencies

NOT APPLICABLE

D. Claims related extra contractual obligations and bad faith losses stemming from lawsuits

NOT APPLICABLE

E. Joint and Several Liabilities

NOT APPLICABLE

F. All Other Contingencies

BCBSA Litigation—Numerous antitrust class actions have been filed against BCBSA and every BCBSM licensees. The cases were originally filed in 2012 and allege that numerous BCBSA rules and/or regulations violate the Sherman Antitrust Act and related state laws. The cases were consolidated into two matters, a provider case and a subscriber case and are currently pending in United States District Court for the Northern District of Alabama. In October 2020, a preliminary settlement was reached in the subscriber matter and BCN paid its portion of the settlement amount in September 2022. Certain entities have opted out of the subscriber settlement and have filed separate legal actions. Additionally, several entities filed Notices of Appeal and intend to appeal the approval of the preliminary settlement to the Eleventh Circuit Court of Appeals. With respect to the opt-out cases, the appeal and the provider action, it is not yet possible to make an assessment regarding the probability of an adverse outcome, nor estimate a range of potential loss.

Other Legal Matters – BCN is a defendant in numerous other lawsuits and involved in other matters arising in the normal course of business primarily related to subscribers' benefits, breach of contracts, provider reimbursement issues and provider participation arrangements. BCN's management, as of December 31, 2022, estimates that these matters will be resolved without a material adverse effect on BCN's future financial position or results of operations.

Where available information indicates that it is probable that a loss has been incurred as of the date of the statutory-basis financial statements and the amount of the loss can be reasonably estimated, BCN will accrue the estimated loss. As of December 31, 2022, and 2021, BCN recorded in general expenses due or accrued in the Liabilities, Capital, and Surplus \$899,000 and \$18,261,596, respectively, for all probable and reasonably estimable losses.

The statements of revenue and expenses for the periods ended December 31, 2022 and December 31, 2021 includes approximately \$3,986,673 and \$0, respectively, related to legal losses and settlements.

Asset Impairment – In accordance with BCN's impairment policy, OTTI is presumed to exist when the market value is below cost for investments managed by outside investment managers, because BCN has delegated the decision to hold the security until recovery and cannot assert the "intent and ability to hold to recovery."

The OTTI fair-value write-down for securities was \$34,582,927 and \$4,905,949 for debt securities and \$12,399,752 and \$6,418,910 for equity securities in 2022 and

Except for the recorded impairment mentioned above, all other investment securities that temporarily have a fair market value that is below amortized cost, are not considered to be impaired.

#### NOTE 15 Leases

- A. Lessee Operating Lease:
  - (1) Leasing arrangements
    - (a) Rent Expense

BCN entered into certain cancelable building leases with BCBSM.

BCN also leases office buildings under noncancelable operating leases with unrelated parties. Rent expense in 2022 and 2021 was \$3,983,490 and \$3,990,372, respectively.

(b) Contingent Rental Payment Basis

NOT APPLICABLE

(c) BCN's corporate office is leased through June 30, 2025. At the expiration of the lease, BCN has the option to extend the lease for three terms of five years.

Lease Restrictions

NOT APPLICABLE

Early Terminations

NOT APPLICABLE

(2) Non-cancelable leases

1. 2023

2. 2024

(a) At December 31, 2022, the minimum aggregate rental commitments are as follows:

Operating Leases

\$ 4,207,201 \$ 4,207,201

\$ 4,207,20

3. 2025	\$ 2,103,600
4. 2026	\$ -
5. 2027	\$ -
6. Thereafter	\$ -
7. Total (sum of 1 through 6)	\$ 10,518,002

(b) Non-cancelable subleases

NOT APPLICABLE

(3) Sale-leaseback transactions

NOT APPLICABLE

B. Lessor Leases

NOT APPLICABLE

NOTE 16 Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

NOT APPLICABLE

#### NOTE 17 Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

NOT APPLICABLE

- B. Transfer and Servicing of Financial Assets
  - (1) Description of any Loaned Securities

BCN participates in security lending agreements with a custodian bank. Under this agreement, BCN lends equity and bond securities in exchange for collateral, approximating at least 103% of the value of the securities loaned. Cash collateral is invested by the custodian bank in a money market fund, while non-cash collateral is in the form of U.S. Treasury and U.S. agency securities. The security lending agreements are primarily overnight in nature and subject to renewal or termination. The fair value of loaned securities at December 31, 2022 were \$5,124,094 and \$7,851,679 for bonds and equities respectively.

(2) Servicing Assets and Servicing Liabilities

NOT APPLICABLE

(3) When Servicing Assets and Liabilities are Measured at Fair Value

NOT APPLICABLE

(4) Securitizations, Asset-Based Financing Arrangements and Similar Transfers Accounted for as Sales

NOT APPLICABLE

(5) Disclosure Requirements for Transfers of Assets Accounted for as Secured Borrowing

NOT APPLICABLE

(6) Transfer of Receivables with Recourse

NOT APPLICABLE

(7) Securities Underlying Dollar Repurchase and Dollar Reverse Repurchase Agreements

NOT APPLICABLE

C. Wash Sales

BCN has no wash sales at December 31, 2022.

#### NOTE 18 Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

#### A. ASO Plans:

The gain (loss) from operations from Administrative Services Only (ASO) uninsured plans and the uninsured portion of partially insured plans was as follows during 2022:

	ASO Uninsured Plans	Uninsured Portion of Partially Insured Plans	I	Total ASO
<ul> <li>a. Net reimbursement for administrative Expenses (including administrative fees) in excess of actual expenses</li> </ul>	\$ (27,654,800)		\$	(27,654,800)
<ul> <li>Total net other income or expenses (including interest paid to or received from plans)</li> </ul>			\$	-
c. Net gain or (loss) from operations (a+b)	\$ (27,654,800)	\$ -	\$	(27,654,800)
d. Total claim payment volume	\$ 805,870,547		\$	805,870,547

#### B. ASC Plans

NOT APPLICABLE

- C. Medicare or Similarly Structured Cost Based Reimbursement Contract
  - (1) Medicare Part D cost-based reimbursements for the years 2022 and 2021 consisted of \$13,000,586 and \$10,002,303, respectively, for coverage gap discount; \$18,527,277 and \$12,481,729, respectively, for low-income subsidy (cost sharing portion); and \$45,988,263 and \$37,903,217, respectively, for reinsurance payments.

(2) As of December 31, 2022 and 2021, respectively, BCN had recorded receivables from the following payors whose account balances were greater than 10% of BCN's amounts receivable from uninsured accident and health plans or \$10,000:

2022 2021

Centers for Medicare & Medicaid Services (CMS)

\$18,037,184 \$16,457,251

- (3) In connection with the Medicare Part D cost-based reimbursement portion of the contract, BCN has recorded no allowances and reserves for adjustment of recorded reimbursement advances as of December 31, 2022 and 2021.
- (4) Adjustments to revenue resulting from an audit of receivables related to revenues recorded in the prior period.

NOT APPLICABLE

#### NOTE 19 Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

NOT APPLICABLE

#### NOTE 20 Fair Value Measurements

- Inputs Used for Assets and Liabilities Measured and Reported at Fair Value
  - Items Measured and Reported at Fair Value by Levels 1, 2 and 3

The fair values BCN's securities are based on quoted market prices, where available. These fair values are obtained primarily from custodian banks or third-party pricing services, which generally use Level 1 or Level 2 inputs for the determination of fair value in accordance with SSAP guidance.

BCN obtains one quoted price for each security, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. For securities not actively traded, the third-party pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates, and prepayment speeds.

In certain circumstances, it may not be possible to derive pricing model inputs from observable market activity, and therefore, such inputs are estimated internally. Such securities are designated Level 3.

The following techniques were used to estimate the fair value and determine the classification of assets pursuant to the valuation hierarchy:

Bonds consist of:

U.S. Government—Consist of certain U.S. government securities and bonds issued by U.S. government-backed agencies. U.S. Government securities are valued based on observable inputs such as the U.S. Treasury yield curve and/or similar assets in markets that are active and are classified as Level

All Other Government—Consists of government securities and bonds issued by foreign government-backed agencies. Valuation is based on prices by a pricing service using a composite yield curve. These securities are classified as Level 2.

Special Revenue and Assessments—Consist of bonds and debt backed by noncorporate entities. Valuation is based on inputs derived directly from observable market data, such as discounted cash flows. These securities are not consistently or actively traded and are classified as Level 2.

Industrial and Miscellaneous—Consist of corporate notes and bonds. Valuation is determined using pricing models maximizing the use of observable inputs for similar securities. This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings. When quoted prices are not available for identical or similar bonds, the security is valued under a discounted cash flows approach that maximizes observable inputs, such as current yields of similar instruments, but includes adjustment for certain risks that may not be observable, such as credit and liquidity risk or a broker quote, if available. These securities are classified as Level 2.

Surplus Notes - are comprised of insurer-specific bonds. Valuation is determined using pricing models mazimizing the use of observable inputs for similar securities. This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings. When quoted prices are not available for identical or similar bonds, the security is valued under a discounted cash flows approach that maximizes observable inputs, such as current yields of similar instruments, but includes adjustment for certain risks that may not be observable, such as credit and liquidity risk or a broker quote, if available. These securities are classified as Level 2.

Common Stocks—Consist of actively traded exchange-listed common stock and mutual fund investments, as well as privately held mutual funds and other private equity investments. The valuation for exchange-traded securities are based on unadjusted quoted prices for these securities, or funds in an active market. These securities are classified as Level 1. If applicable, certain private equity investments would be classified as Level 3, valued using external pricing, supplemented by internal review and anlysis.

Mutual Funds—Consist of registered mutual funds actively traded on an open exchange. The public-traded funds are based on an observable price in an active market and; therefore, classified as Level 1.

Cash Equivalents and Short-Term Investments—Consist of commercial paper, discount notes, other money market mutual funds, and other investments with original maturities of one year or less. Valuation is based on unadjusted quoted prices. These securities are classified as Level 1. Valuation for commercial paper and other securities is based on inputs derived from observable market data and are classified as Level 2.

Exempt Money Market Funds—Consist of money market funds that invest in one of the following: securities that are direct obligations of the U.S. government, securities that are backed by the full faith and credit of the U.S. government or collateralized repurchase agreements composed of such obligations. The Securities Valuation Office of the National Association of Insurance Commissioners maintains the list of money market funds that are eligible for classification as Exempt Money Market Funds. These securities are classified as Level 1.

Other Money Market Mutual Funds—are recorded at fair value or net asset value (NAV) per share. These securities are classified as Level 1.

State Street Navigator Securities Lending—Consists of the cash collateral posted on securities lending transactions and reinvested in money market securities. These securities are classified as Level 1.

BON'S assets and liabilities measured	BCN's assets and liabilities measured and recorded at fair value as of December 31, 2022, are as follows:										
Description for each class of asset or liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total						
a. Assets at fair value											
Bonds					\$	-					
Exchange Traded Funds - as Identified by SVO	\$ 1,664,264				\$ 1,664,26	34_					
Common Stock					\$	-					
Industrial and miscellaneous (Unaffiliated)	\$ 160,737,921				\$ 160,737,92	21					
Mutual Funds	\$ 987,164				\$ 987,16	34					
Cash Equilalents					\$	-					
Exempt money market mutual funds	\$ 1,008,381				\$ 1,008,38	31					
Other money market mutual funds	\$ 3,503,083				\$ 3,503,08	33					
Other					\$	-					
Securities lending collateral	\$ 11,249,884				\$ 11,249,88	34					

Total assets at fair value/NAV	\$ 179,150,697	\$	-	\$ -	\$ -	\$ 179,150,697
Description for each class of asset or liability	(Level 1)	(Level 2)		(Level 3)	Net Asset Value (NAV)	Total
b. Liabilities at fair value Payables for securities lending	\$ 11,249,884					\$ 11,249,884
Total liabilities at fair value	\$ 11,249,884	\$	- [	\$ -	\$ -	\$ 11,249,884

- (2) Fair Value Measurements in (Level 3) of the Fair Value hierarchy
  - NOT APPLICABLE
- (3) Transactions between levels
  - **NOT APPLICABLE**
- (4) Certain assets and liabilities of BCN are measured and reported: (a) at amortized cost, (b) at values using the adjusted audited GAAP equity method, or (c) at values that approximate fair value due to their liquid or short-term nature.
- (5) Derivative assets and liabilities

NOT APPLICABLE

B. Other Fair Value Information

**NOT APPLICABLE** 

C. Aggregate fair value or NAV for all financial instruments and the level within the fair value hierarchy in which the fair value measurements in their entirety fall.

Type of Financial Instrument	Aggregate Fair Value	A	dmitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Assets:								
Bonds								
Special revenue and assessment obligations Industrial and miscellaneous	\$ 309,728,786 666,056,465	\$	344,952,522 687,995,914		\$ 309,728,786 666,056,465			
U.S. Governments	\$ 329,496,705	\$	363,513,021		\$ 329,496,705			
Other Countries Government	\$ 1,446,687	\$	1,691,383		\$ 1,446,687			
ETF Bonds Identified by SVO	\$ 1,664,264	\$	1,664,264	\$ 1,664,264				
Surplus Notes	\$ 10,888,695	\$	10,887,636		\$ 10,888,695			
Common Stock Industrial and miscellaneous (unaffiliated)	\$ 160,737,921	\$	160,737,921	\$ 160,737,921				
Mutual Funds	\$ 987,164	\$	987,164	\$ 987,164				
Cash Equivalents and Short Term Investments Industrial and miscellaneous (unaffiliated)	\$ 495,533,732	\$	496,614,183		\$ 495,533,732			
Exempt money market mutual funds	\$ 1,008,381	\$	1,008,381	\$ 1,008,381				
Other money market funds Governments	\$ 3,503,083 438,392	\$ \$	3,503,083 438,362	\$ 3,503,083	\$ 438,392			
Other: Securities lending collateral	\$ 11,249,884	\$	11,249,884	\$ 11,249,884				
Liabilities:								
Debt	\$ 47,576,992	\$	50,000,000			\$ 47,576,992		
Payable for securities lending	\$ 11,249,884	\$	11,249,884	\$ 11,249,884				

D. Not Practicable to Estimate Fair Value

BCN held no securities at December 31, 2022 and December 31, 2021 where it was not practicable to determine the fair value of the investment.

E. Investments Using the NAV Practical Expedient NOT APPLICABLE

#### NOTE 21 Other Items

A. Unusual or Infrequent Items

NOT APPLICABLE

B. Troubled Debt Restructuring: Debtors

NOT APPLICABLE

C. Other Disclosures

Statutory Deposit – As a condition of maintaining its certificate of authority with the State of Michigan, BCN maintains a deposit in a segregated account of \$1,000,000, which is the maximum required for a Health Maintenance Organization. These funds are intended to be used for the sole benefit of all BCN members, and only at the direction of the Director of DIFS. The funds are invested in an exempt money market mutual fund and reported in cash equivalents, in accordance with SSAP No. 2R - Cash, Cash Equivalents, Drafts and Short-Term Investments. Interest on these funds accrues to BCN.

Industry Concentration – BCN conducts business primarily within the state of Michigan. A significant portion of BCN's customer base is concentrated in companies that are part of the automobile manufacturing industry. Receivables from those customers were \$7,014,525 and \$1,822,529, as of December 31, 2022 and 2021, respectively. In addition, BCN held investments in these customers with a total value of \$23,513,862 and \$16,715,357, as of December 31, 2022 and 2021, respectively.

D. Business Interruption Insurance Recoveries

NOT APPLICABLE

E. State Transferable and Non-transferable Tax Credits

NOT APPLICABLE

F. Subprime Mortgage Related Risk Exposure

NOT APPLICABLE

G. Retained Assets

NOT APPLICABLE

H. Insurance-Linked Securities (ILS) Contracts

NOT APPLICABLE

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

NOT APPLICABLE

#### NOTE 22 Events Subsequent

Management has evaluated all events subsequent to the annual statement date of December 31, 2022, through March 1, 2023, for the annual statement submitted on March 1, 2023.

Type I - Recognized Subsequent Events:

Management has determined that there are no Type I subsequent events that require disclosure under SSAP No. 9, Subsequent Events.

Type II - Nonrecognized Subsequent Events:

Management has determined that there are no Type II subsequent events that require disclosure under SSAP No. 9, Subsequent Events.

#### NOTE 23 Reinsurance

#### A. Ceded Reinsurance Report

In compliance with the NAIC annual statement instructions and SSAP No. 61R, Life, Deposit-Type and Accident and Health Reinsurance, BCN accounts for its transactions with BCBSM as ceded reinsurance. BCBSM covers inpatient and outpatient facility claims in excess of \$300,000 per member basis for all lines of business, up to a defined accumulated attachment point of \$9.719 per member per month for Medicare Advantage and \$14.411 per member per month for Group Commercial Business, and \$13.388 for Individual health insurance business. In addition, BCBSM provides insolvency coverage subject to a separate aggregate limit in the amount of \$5,000,000 for all policies combined.

Section 1 – General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

Yes() No (X)

If yes, give full details.

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or any other person not primarily engaged in the insurance business?

Yes() No (X)

If yes, give full details

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credit?

Yes ( ) No (X)

- a. If yes, what is the estimated amount of the aggregate reduction in surplus of a unilateral cancellation by the reinsurer as of the date of this statement, for those agreements in which cancellation results in a net obligation of the reporting entity to the reinsurer, and for which such obligation is not presently accrued? Where necessary, the reporting entity may consider the current or anticipated experience of the business reinsured in making this estimate. NOT APPLICABLE
- b. What is the total amount of reinsurance credits taken, whether as an asset or as a reduction of liability for these agreements in this statement? NOT APPLICABLE
- (2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes ( ) No (X)

If yes, give full details.

Section 3 - Ceded Reinsurance Report - Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate \$0
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?

Yes () No (X

If yes, what is the amount of reinsurance credits, whether an asset or a reduction of liability, taken for such new agreements or amendments? NOT APPLICABLE

B. Uncollectible Reinsurance

NOT APPLICABLE

C. Commutation of Reinsurance Reflected in Income and Expenses

**NOT APPLICABLE** 

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation

NOT APPLICABLE

E. Reinsurance Credit

**NOT APPLICABLE** 

#### NOTE 24 Retrospectively Rated Contracts & Contracts Subject to Redetermination

A. BCN estimates accrued redetermination premium adjustments and return premium adjustments for its group health insurance contracts subject to redetermination based on an examination of contract requirements in relation to the rates charged for similarly sized subscriber groups, and the status of past applicable audits.

BCN estimates accrued retrospective premium adjustments for its Medicare Advantage health insurance contracts based on an analysis of Part C member health risk score adjustments submitted to CMS and the Part D risk corridor reconciliation related to the funds received from CMS or the beneficiary.

To the extent that BCN is subject to potential medical loss ratio (MLR) rebates, any return premium adjustment would be based on the formulas required by law.

- B. Accrued redetermination premium adjustments and return premium adjustments, as well as retrospective premiums, are recorded as adjustments to earned premium revenue.
- C. The amount of net premiums, written by BCN, that were subject to redetermination or retrospective provisions (including premiums subject to MLR rebates) was \$4,122,711,152 and \$3,881,447,330 for 2022 and 2021, respectively; representing approximately 99.3% and 99.2% of the total net health premiums written for 2022 and 2021, respectively. No other premiums written by BCN were subject to redetermination or retrospective provisions.
- D. Medical loss ratio rebates required pursuant to the Public Health Service Act.

	1		2		3		4 Other		5	
		S	Small Grou	up	L	Large Group		Categories with		
	Individual		Employer		Employer				Rebates	Total
Prior Reporting Year										
(1) Medical loss ratio rebates incurred	\$ 1,485,399	\$		-	\$		-	\$	101,664	\$ 1,587,063
(2) Medical loss ratio rebates paid	\$ 14,582,191	\$		-	\$		-	\$	102,184	\$ 14,684,375
(3) Medical loss ratio rebates unpaid	\$ 9,058,848	\$		-	\$		-	\$	109,246	\$ 9,168,094
(4) Plus reinsurance assumed amounts	XXX		XXX			XXX			XXX	
(5) Less reinsurance ceded amounts	XXX		XXX			XXX			XXX	
(6) Rebates unpaid net of reinsurance	XXX		XXX			XXX			XXX	\$ 9,168,094
Current Reporting Year-to-Date										
(7) Medical loss ratio rebates incurred	\$ 2,412,000	\$		-	\$		-	\$	-	\$ 2,412,000
(8) Medical loss ratio rebates paid	\$ 14,017	\$		-	\$		-	\$	1,844	\$ 15,861
(9) Medical loss ratio rebates unpaid	\$ 11,456,831	\$		-	\$		-	\$	107,402	\$ 11,564,233
(10) Plus reinsurance assumed amounts	XXX		XXX			XXX			XXX	
(11) Less reinsurance ceded amounts	XXX		XXX			XXX			XXX	
(12) Rebates unpaid net of reinsurance	XXX		XXX			XXX			XXX	\$ 11,564,233

- E. Risk Sharing Provisions of the Affordable Care Act
  - (1) Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions (YES/NO)?

Yes [X] No []

(2) Impact of Risk Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities and Revenue for the Current Year

Amount

a. Permanent ACA Risk Adjustment Program

Assets

1. Premium adjustments receivable due to ACA Risk Adjustment (including high risk pool payments) Liabilities

Risk adjustment user fees payable for ACA Risk Adjustment

\$ 1,002,710

3. Premium adjustments payable due to ACA Risk Adjustment (including high risk pool premium) Operations (Revenue & Expense)

\$ 34,691,640

4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment

\$ (6,121,341)

5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)

\$ 685,987

b. Transitional ACA Reinsurance Program

Assets

- Amounts recoverable for claims paid due to ACA Reinsurance
- 2. Amounts recoverable for claims unpaid due to ACA Reinsurance (Contra Liability)

Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance Liabilities

- 4. Liabilities for contributions payable due to ACA Reinsurance not reported as ceded premium
- 5. Ceded reinsurance premiums payable due to ACA Reinsurance
- 6. Liabilities for amounts held under uninsured plans contributions for ACA Reinsurance

Operations (Revenue & Expense)

- 7. Ceded reinsurance premiums due to ACA Reinsurance
- 8. Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments
- 9. ACA Reinsurance contributions not reported as ceded premium

c. Temporary ACA Risk Corridors Program

Assets

1. Accrued retrospective premium due to ACA Risk Corridors Liabilities

- 2. Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors
- Operations (Revenue & Expense)
  - 3. Effect of ACA Risk Corridors on net premium income (paid/received)
  - 4. Effect of ACA Risk Corridors on change in reserves for rate credits

(3) Roll forward of prior year ACA risk sharing provisions for the following asset (gross of any nonadmission) and liability balances along with the reasons for adjustments to prior year halones.

for adjustments to prior ye											
		d During r Year on		or Paid as of ont Year on	Differ	rences	A	djustments			alances as of rting Date
	Before De	es Written ecember 31 Prior Year	Before De	s Written ecember 31 rior Year	Prior Year Accrued Less Payments (Col 1 - 3)	Prior Year Accrued Less Payments (Col 2 - 4)	To Prior Year Balances	Prior Year Prior Year		Cumulative Balance from Prior Years (Col 1-3+7)	Cumulative Balance from Prior Years (Col 2-4+8)
	1 Dessivable	2 Develo	3 Dessivable	4 Payable	5 Dessivable	6 Payable	7 Descivable	8 Davable	Def	9 Dessivable	10
a. Permanent ACA Risk Adjustment Program	Receivable	Payable	Receivable	Payable	Receivable	Payable	Receivable	Payable	Ref	Receivable	Payable
Premium adjustments receivable (including high risk pool payments)					\$ -	\$ -			Α	\$ -	\$ -
Premium adjustments (payable) (including high risk pool premium)		\$58,067,099		\$30,031,443	\$ -	\$28,035,656		\$ (33,155,927)	В	\$ -	\$(5,120,271)
3. Subtotal ACA Permanent Risk Adjustment Program	\$ -	\$58,067,099	\$ -	\$30,031,443	\$ -	\$28,035,656	\$ -	\$ (33,155,927)		\$ -	\$(5,120,271)
b. Transitional ACA Reinsurance Program											
Amounts recoverable for claims paid					\$ -	\$ -			С	\$ -	\$ -
Amounts recoverable for claims unpaid (contra liability)					\$ -	\$ -			D	\$ -	\$ -
Amounts receivable relating to uninsured plans					\$ -	\$ -			E	\$ -	\$ -
Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded											
premium 5. Ceded reinsurance premiums payable					\$ - \$ -	\$ - \$ -			F G	\$ - \$ -	\$ - \$ -
6. Liability for amounts held under uninsured plans					\$ -	\$ -			Н	\$ -	\$ -
7. Subtotal ACA Transitional Reinsurance Program	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
c. Temporary ACA Risk Corridors Program											
Accrued retrospective premium					\$ -	\$ -			1	\$ -	\$ -
Reserve for rate credits or policy experience rating refunds					\$ -	\$ -			J	\$ -	\$ -
Subtotal ACA Risk     Corridors Program	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
d. Total for ACA Risk Sharing Provisions	\$ -	\$58,067,099	\$ -	\$30,031,443	\$ -	\$28,035,656	\$ -	\$ (33,155,927)		\$ -	\$(5,120,271)

A.

Adjustment supplied by CMS.

D.

Ε.

F. G.

Н.

I.

J.

(4) Roll-Forward of Risk Corridors Asset and Liability Balances by Program Benefit Year

	the Prior Busines Before De	d During r Year on ss Written cember 31 rior Year	Received or Paid as of the Current Year on Business Written Before December 31 of the Prior Year		Differ Prior Year Accrued Less Payments (Col 1 - 3)	Accrued Accrued Less Less Payments Payments		Adjustments  To To To Prior Year Balances Balances			alances as of rting Date Cumulative Balance from Prior Years (Col 2-4+8)	
	1	2	3	4	5	6	7	8		9	10	
	Receivable	Payable	Receivable	Payable	Receivable	Payable	Receivable	Payable	Ref	Receivable	Payable	
a. 2014												
Accrued retrospective premium					\$ -	\$ -			А	\$ -	\$ -	
2. Reserve for rate credits or policy experience rating refunds					\$ -	\$ -			В	\$ -	\$ -	

		Ī	I	1		1 1	ı		1
		\$ -	\$ -			С	\$ -	\$	-
		\$ -	\$ -			D	\$ -	\$	-
		\$ -	\$ -			E	\$ -	\$	-
٠		\$ -	\$ -			F	\$ -	\$	-
	e		\$ - \$ -	\$ - \$ - \$ - \$	\$ - \$ - \$ - \$ -	\$ - \$ - \$ - \$ - \$ - \$	\$ - \$ - D \$ - \$ - F	\$ - \$ - D \$ - E \$ - F \$ -	\$ - \$ - \$ D \$ - \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$

**Explanations of Adjustments** 

A.

B.

C.

D.

E.

F.

24E(4)d (Columns 1 through 10) should equal 24E(3)c3 (Column 1 through 10 respectively)

(5) ACA Risk Corridors Receivable as of Reporting Date

(3) ACA Trisk Corndors Receivable as of Reporting E	aic					
	1	2	3	4	5	6
	Estimated Amount to be Filed or Final Amount Filed	Non-Accrued Amounts for Impairment or Other	Amounts received from	Asset Balance (Gross of Non- admissions)	Non-admitted	Net Admitted
Risk Corridors Program Year	with CMS	Reasons	CMS	(1-2-3)	Amount	Asset (4 - 5)
a. 2014	\$ 17,193,568		\$ 17,193,568	\$ -		\$ -
b. 2015	\$ 4,131,999		\$ 4,131,999	\$ -		\$ -
c. 2016	\$ 20,617,732		\$ 20,617,732	\$ -		\$ -
d. Total (a + b + c)	\$ 41,943,299	\$ -	\$ 41,943,299	\$ -	\$ -	\$ -

24E(5)d (Column 4) should equal 24E(3)c1 (Column 9)

24E(5)d (Column 6) should equal 24E(2)c1

BCN received its risk corridor receivables from the federal government in November, 2020. BCN is currently under a MLR audit examination for the 2017 - 2019 reporting years. As agreed upon during the audit, BCN has not yet paid additional rebates to enrollees related to the risk corridor funds received. No financially material findings are anticipated.

#### NOTE 25 Change in Incurred Claims and Claim Adjustment Expenses

A. Liabilities for unpaid claims and claims adjustment expenses as of December 31, 2021, were \$435,179,347. As of December 31, 2022, \$421,891,869 has been paid for incurred claims and claims adjustment expenses attributable to insured events of prior years, respectively. Liabilities for unpaid claims and claims adjustment expenses remaining for prior years are now estimated to be \$1,264,547 as a result of a re-estimation of unpaid claims on comprehensive and Medicare lines of business. Therefore, there has been a \$12,022,931 favorable prior year development based on the analysis of recent loss development trends from December 31, 2022.

B. Significant Changes in Methodologies and Assumptions

NOT APPLICABLE

#### NOTE 26 Intercompany Pooling Arrangements

NOT APPLICABLE

#### NOTE 27 Structured Settlements

NOT APPLICABLE

#### NOTE 28 Health Care Receivables

#### A. Pharmaceutical Rebate Receivables

Health care receivables include pharmacy rebates BCN receives from a third-party vendor. BCN estimates pharmacy rebate receivables based on historical rebate experience and membership. Activity for the most recent three years is summarized as follows:

Date	Estimated Pharmacy Rebates as Reported on Financial Statements	_	Pharmacy bates as Billed or Otherwise Confirmed	Re	ctual Rebates eceived Within Days of Billing	Re	ctual Rebates eceived Within to 180 Days of Billing	R	ctual Rebates eceived More han 180 Days After Billing
12/31/2022	\$ 83,182,464	\$	1	\$	1	\$		\$	-
09/30/2022	\$ 84,995,533	\$	87,558,967	\$	87,559,967	\$	-	\$	-
06/30/2022	\$ 84,272,552	\$	91,967,573	\$	91,992,302	\$	(24,729)	\$	-
03/31/2022	\$ 83,129,733	\$	80,901,136	\$	80,389,335	\$	518,426	\$	(6,625)
12/31/2021	\$ 76,642,829	\$	69,326,482	\$	58,231,657	\$	22,546,814	\$	1,080,764
09/30/2021	\$ 74,092,592	\$	75,469,744	\$	65,908,863	\$	763,231	\$	8,797,650
06/30/2021	\$ 75,844,872	\$	82,225,812	\$	69,016,252	\$	840,450	\$	12,369,110
03/31/2021	\$ 71,356,818	\$	77,955,787	\$	61,489,613	\$	526,826	\$	15,939,348
12/31/2020	\$ 64,370,119	\$	68,694,243	\$	62,052,079	\$	6,555,548	\$	86,616
09/30/2020	\$ 61,140,361	\$	63,676,671	\$	56,714,606	\$	885,914	\$	6,076,151
06/30/2020	\$ 61,827,763	\$	66,957,345	\$	57,864,988	\$	1,451,766	\$	7,640,591
03/31/2020	\$ 64,678,688	\$	68,975,905	\$	56,857,693	\$	1,515,382	\$	10,602,830

#### B. Risk-Sharing Receivables

Estimated risk sharing receivables are actuarially determined based on current year and adjusted for seasonally of claims, risk and revenue. Risk sharing receivables at December 31, 2022 are summarized in the following table.

Calendar Year	Evaluation Period Year Ending	Risk Sharing Receivable as Estimated in the Prior Year	Risk Sharing Receivable as Estimated in the Current Year	Risk Sharing Receivable Billed	Risk Sharing Receivable Not Yet Billed	Actual Risk Sharing Amounts Received in Year Billed	Actual Risk Sharing Amounts Received First Year Subsequent	Actual Risk Sharing Amounts Received Second Year Subsequent	Actual Risk Sharing Amounts Received - All Other
2022	2022 2023	-	- 5,962,877	-	-	-			
2021	2021 2022	-	-	-	-	-	-		
2020	2020 2021	-	-	-	-	-	-	-	

#### NOTE 29 Participating Policies

NOT APPLICABLE

#### NOTE 30 Premium Deficiency Reserves

NOT APPLICABLE

#### NOTE 31 Anticipated Salvage and Subrogation

BCN did not reduce its liability for unpaid claims/losses by any estimated anticipated salvage and subrogation at December 31, 2022 or 2021 as BCN records salvage and subrogation on a paid basis when cash is received.

#### **GENERAL INTERROGATORIES**

# PART 1 - COMMON INTERROGATORIES GENERAL

1.1	is an insurer?	stem consisting of two or more affiliated persons, one or more of which	Yes [ X ] No [ ]
	If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.		
1.2	If yes, did the reporting entity register and file with its domiciliary State such regulatory official of the state of domicile of the principal insurer is providing disclosure substantially similar to the standards adopted by the tits Model Insurance Holding Company System Regulatory Act and mosubject to standards and disclosure requirements substantially similar	n the Holding Company System, a registration statement he National Association of Insurance Commissioners (NAIC) in	X ] No [ ] N/A [ ]
1.3	State Regulating?		Michigan
1.4	Is the reporting entity publicly traded or a member of a publicly traded	group?	Yes [ ] No [ X ]
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code	issued by the SEC for the entity/group	
2.1	Has any change been made during the year of this statement in the ch reporting entity?	arter, by-laws, articles of incorporation, or deed of settlement of the	Yes [ X ] No [ ]
2.2	If yes, date of change:		08/16/2022
3.1	State as of what date the latest financial examination of the reporting e	entity was made or is being made	12/31/2020
3.2	State the as of date that the latest financial examination report became entity. This date should be the date of the examined balance sheet and	e available from either the state of domicile or the reporting d not the date the report was completed or released	12/31/2020
3.3	State as of what date the latest financial examination report became a domicile or the reporting entity. This is the release date or completion examination (balance sheet date).	date of the examination report and not the date of the	10/15/2021
3.4	By what department or departments?  Department of Insurance and Financial Services		
3.5	Have all financial statement adjustments within the latest financial exa statement filed with Departments?	mination report been accounted for in a subsequent financial Yes [	] No [ ] N/A [ X ]
3.6	Have all of the recommendations within the latest financial examination	n report been complied with? Yes [	X ] No [ ] N/A [ ]
4.1	a substantial part (more than 20 percent of any major line of business 4.11 sale	yees of the reporting entity), receive credit or commissions for or control	Yes [ ] No [ X ] Yes [ ] No [ X ]
4.2		anization owned in whole or in part by the reporting entity or an affiliate,	165 [ ] NO [ X ]
	4.21 sale	es of new business?	Yes [ ] No [ X ] Yes [ ] No [ X ]
5.1	Has the reporting entity been a party to a merger or consolidation durin If yes, complete and file the merger history data file with the NAIC.	ng the period covered by this statement?	Yes [ ] No [ X ]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state ceased to exist as a result of the merger or consolidation.	of domicile (use two letter state abbreviation) for any entity that has	
	1 Name of Entity	2 NAIC Company Code State of Domicile	
6.1	, , , ,	egistrations (including corporate registration, if applicable) suspended or	Yes [ ] No [ X ]
6.2	If yes, give full information:		
7.1		ctly control 10% or more of the reporting entity?	Yes [ ] No [ X ]
7.2	If yes, 7.21 State the percentage of foreign control;		%
	1 Nationality	2 Type of Entity	
	errenney	71J	

8.1 8.2	Is the company a subsidiary of a depository institution holding compa If the response to 8.1 is yes, please identify the name of the DIHC.					Yes [	]	No [	[ X ]	
8.3	Is the company affiliated with one or more banks, thrifts or securities	firms?				Yes [ X	1	No [	. 1	
8.4	If response to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission	on (city and state of the main office) of any affiliates ree Office of the Comptroller of the Currency (OCC), the	egulated he Feder	by a fed al Depo	deral	103 [ A	1	NO [		
	1	2	3	4	5	6	1			
	Affiliate Name Bricktown Capital LLC	Location (City, State)	FRB	OCC	FDIC		4			
	Bricktown Capital LLC		N0		NO					
8.5	Is the reporting entity a depository institution holding company with significant company with s	gnificant insurance operations as defined by the Boa	ard of Go	vernors	of					
8.6	Federal Reserve System or a subsidiary of the depository institution half response to 8.5 is no, is the reporting entity a company or subsidiar Federal Reserve Board's capital rule?	y of a company that has otherwise been made subje	ect to the			Yes [ ] No [	-		_	1
9.	What is the name and address of the independent certified public acc					1 [	1	,		•
	Deloitte & Touche LLP, 200 Renaissance Center, Suite 3900, Detroit									
10.1	Has the insurer been granted any exemptions to the prohibited non-a requirements as allowed in Section 7H of the Annual Financial Repor law or regulation?	rting Model Regulation (Model Audit Rule), or substa	intially si	milar sta	ite	Yes [	1	No [	X 1	
10.2	If the response to 10.1 is yes, provide information related to this exen	nption:					•	•		
10.3 10.4	Has the insurer been granted any exemptions related to the other regallowed for in Section 18A of the Model Regulation, or substantially significant to the response to 10.3 is yes, provide information related to this exemption.	uirements of the Annual Financial Reporting Model imilar state law or regulation?	Regulati	on as		Yes [	]	No [	[ X ]	
10.5	Has the reporting entity established an Audit Committee in compliance					V 1 N F	,	N		,
10.5		e with the domicinary state insurance laws:			res [ /	X ] NO [	J	N/F	4 [	J
<ul><li>11.</li><li>12.1</li></ul>	What is the name, address and affiliation (officer/employee of the rep firm) of the individual providing the statement of actuarial opinion/cert Kirk Roy, FSA, MAAA, Sr. Vice President and Chief Actuary, Blue Cn 48226  Does the reporting entity own any securities of a real estate holding c	itification? oss Blue Shield of Michigan, 600 Lafayette East, MC	C 1701, [	Detroit, N	ЛI	Yes [ X	]	No [	]	
	12.11 Name of real	estate holding company Alidade V						·	-	
	12.12 Number of pa	Brookfield arcels involved				849				
		djusted carrying value						17,2	279, 18	32
12.2	If, yes provide explanation:	, , , ,								
	These are limited partnerships with Real Estate portfolios									
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTIT	FIES ONLY:								
13.1	What changes have been made during the year in the United States		•							
13.2	Does this statement contain all business transacted for the reporting Have there been any changes made to any of the trust indentures du	, ,	rever loc	ated?			-	No [	-	
13.3	If answer to (13.3) is yes, has the domiciliary or entry state approved	0 ,					•	No [		,
13.4 14.1	Are the senior officers (principal executive officer, principal financial of					] No [	]	IN/ F	A [	J
17.1	similar functions) of the reporting entity subject to a code of ethics, what a. Honest and ethical conduct, including the ethical handling of actual relationships;	hich includes the following standards?	· · · · · · · · · · · · · · · · · · ·			Yes [ X	]	No [	]	
	b. Full, fair, accurate, timely and understandable disclosure in the per c. Compliance with applicable governmental laws, rules and regulation		tity;							
	d. The prompt internal reporting of violations to an appropriate persor e. Accountability for adherence to the code.	n or persons identified in the code; and								
14.11	If the response to 14.1 is No, please explain:									
14.2	Has the code of ethics for senior managers been amended?					Yes [ X	]	No [	1	
14.21	1 If the response to 14.2 is yes, provide information related to amendment(s).					-	-		-	
	Updates to the Code of Ethics focused on aligning responsibilities wit language with regulatory updates									
	Have any provisions of the code of ethics been waived for any of the					Yes [	]	No [	Χ]	
14.31	If the response to 14.3 is yes, provide the nature of any waiver(s).									

5.1		entity the beneficiary of a Letter of Credit that is unrelated to rein			l seV	] No [ X
5.2	If the response to	o 15.1 is yes, indicate the American Bankers Association (ABA er of Credit and describe the circumstances in which the Letter	) Routing Number	and the name of the issuing or confirming	103 [	) NO [ X
	1 American Bankers Association (ABA) Routing	2		3	4	
	Number	Issuing or Confirming Bank Name		hat Can Trigger the Letter of Credit	Amo	
<b>5</b> .		or sale of all investments of the reporting entity passed upon eit		directors or a subordinate committee	v . r v	
	Does the reporting	ng entity keep a complete permanent record of the proceedings	of its board of dire	ctors and all subordinate committees	Yes [ X	] No [ ] No [
	Has the reporting part of any of its	g entity an established procedure for disclosure to its board of cofficers, directors, trustees or responsible employees that is in	directors or trustees conflict or is likely t	of any material interest or affiliation on the o conflict with the official duties of such	-	
	person?				Yes [ X	] No [
			NCIAL			
	Accounting Prince	ent been prepared using a basis of accounting other than Statut ciples)?				
1	Total amount loa	aned during the year (inclusive of Separate Accounts, exclusive	of policy loans):			
				20.12 To stockholders not officers	\$	
				20.13 Trustees, supreme or grand		
				(Fraternal Only)	\$	
		loans outstanding at the end of year (inclusive of Separate Acc	ounts, exclusive of	20.21 To directors or other officers	•	
	policy loans):					
				20.22 To stockholders not officers	\$	
				(Fraternal Only)	\$	
	Were any assets	s reported in this statement subject to a contractual obligation to reported in the statement?	transfer to anothe	r party without the liability for such		
		amount thereof at December 31 of the current year:		21.21 Rented from others	\$	
	•	•		21.22 Borrowed from others		
				21.23 Leased from others		
				21.24 Other		
	Does this statem	nent include payments for assessments as described in the Anr	nual Statement Inst		ψ	
	guaranty associa	ation assessments?			Yes [ X	] No [
	If answer is yes:			.21 Amount paid as losses or risk adjustmen		
			22	.22 Amount paid as expenses	\$	16,767,
				.23 Other amounts paid		
	Does the reporting	ng entity report any amounts due from parent, subsidiaries or at				
	If yes, indicate a	ny amounts receivable from parent included in the Page 2 amo	unt:		\$	59.048.
	Does the insurer	r utilize third parties to pay agent commissions in which the amo	ounts advanced by	the third parties are not settled in full within	Yes [	
		o 24.1 is yes, identify the third-party that pays the agents and w				
			Is the Third-Party Age	nt		
		Name of Third-Party	a Related Part (Yes/No)			
		Name of Tillian arty	(165/110)			
		INVES	TMENT			
1	More all the st			a reporting ontity has southern a section.		
1		cks, bonds and other securities owned December 31 of current ession of the reporting entity on said date? (other than securities			Yes [ X	] No [

25.02	If no, give full and comple							
25.03	whether collateral is carrie	ed on or off-balance sheet. (an alt	ernative is to	ncluding value for collateral and amount of loaned securities, and or reference Note 17 where this information is also provided)				
25.04	For the reporting entity's s	securities lending program, report	amount of c	ollateral for conforming programs as outlined in the Risk-Based Capital	\$		2,078	,591
25.05				ollateral for other programs.				
25.06				s) and 105% (foreign securities) from the counterparty at the	X ] No	[ ]	N/A [	[ ]
25.07	Does the reporting entity	non-admit when the collateral rec	eived from th	ne counterparty falls below 100%? Yes [	X ] No	[ ]	N/A [	. ]
25.08				ent utilize the Master Securities lending Agreement (MSLA) to Yes [	X ] No	[ ]	N/A [	
25.09	For the reporting entity's	securities lending program state t	he amount o	f the following as of December 31 of the current year:				
	25.092 T	otal book adjusted/carrying value	of reinveste	eported on Schedule DL, Parts 1 and 2d collateral assets reported on Schedule DL, Parts 1 and 2the liability page.	.\$	1	1,249	,884
26.1	Were any of the stocks, be control of the reporting en	onds or other assets of the report	ting entity ow d or transferr	vned at December 31 of the current year not exclusively under the red any assets subject to a put option contract that is currently in				
26.2		nereof at December 31 of the curr		26.21 Subject to repurchase agreements 26.22 Subject to reverse repurchase agreements 26.23 Subject to dollar repurchase agreements 26.24 Subject to reverse dollar repurchase agreements 26.25 Placed under option agreements 26.25 Placed under option agreements 26.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock 26.27 FHLB Capital Stock 26.28 On deposit with states 26.29 On deposit with other regulatory bodies 26.30 Pledged as collateral - excluding collateral pledged an FHLB	\$\$\$\$\$\$\$		3,973	3,400
				26.32 Other	\$	8	39,059	9,353
26.3	For category (26.26) prov	ide the following:						
		1 Nature of Restriction		2 Description		3 nount		
								_
27.1	Does the reporting entity	have any hedging transactions re	ported on Sc	chedule DB?	Yes [	] N	√o [ X	[ ]
27.2	If yes, has a comprehens If no, attach a description		gram been n	nade available to the domiciliary state?	] No	[ ]	N/A [	. ]
INES 2	27.3 through 27.5: FOR LIF	FE/FRATERNAL REPORTING EN	NTITIES ON	LY:				
27.3	Does the reporting entity	utilize derivatives to hedge variab	le annuity gu	parantees subject to fluctuations as a result of interest rate sensitivity? .	Yes [	] N	10 [	]
27.4	If the response to 27.3 is	YES, does the reporting entity util	27.41 Spe 27.42 Per	ecial accounting provision of SSAP No. 108mitted accounting practiceer accounting guidance	Yes [		lo [ lo [ lo [	]
27.5	following:  The reporting en Hedging strategy Actuarial certifice reserves and pro Financial Officer Hedging Strategy	titly has obtained explicit approval or subject to the special accounting ation has been obtained which ind wides the impact of the hedging so Certification has been obtained w	from the do p provisions i licates that the trategy withing which indicate	provisions of SSAP No. 108, the reporting entity attests to the miciliary state.  Is consistent with the requirements of VM-21.  The hedging strategy is incorporated within the establishment of VM-21 in the Actuarial Guideline Conditional Tail Expectation Amount.  The hedging strategy meets the definition of a Clearly Defined edging Strategy is the hedging strategy being used by the company in	Yes [	] N	lo [	]
28.1				current year mandatorily convertible into equity, or, at the option of the	Yes [	] N	No [ X	( 1
28.2		•			-	-	-	-
29.	offices, vaults or safety de custodial agreement with	eposit boxes, were all stocks, bon a qualified bank or trust company	ds and other in accordan	mortgage loans and investments held physically in the reporting entity's recurities, owned throughout the current year held pursuant to a note with Section 1, III - General Examination Considerations, F. as of the NAIC Financial Condition Examiners Handbook?	Yes [	X]N	lo [	]
20.01								
29.01	For agreements that com		IAIC Financia	al Condition Examiners Handbook, complete the following:				
29.01	Name State Street Bank and T	ply with the requirements of the N  1 of Custodian(s) rust Company	801 Pennsy	al Condition Examiners Handbook, complete the following:  2 Custodian's Address /Ivania, Kansas City, M0 64205				

#### **GENERAL INTERROGATORIES**

29.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1	2	3
Name(s)	Location(s)	Complete Explanation(s)

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason
	i		

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
Bricktown Capital, LLC	A
Snyder Capital Management L. P.	U
Los Angeles Capital Management & Equity Research Inc.	
Arrowstreet Capital Limited Partnership	U
Aegon USA Investment Management	U
<u> </u>	

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") manage more than 10% of the reporting entity's invested assets?.....

Yes [ ] No [ X ]

29.0598 For firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets?.....

Yes [ ] No [ X ]

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
				Investment
				Management
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
319290	Bricktown Capital, LLC	2549000B61KVCB6L0U24	SEC	NO
108518	Snyder Capital Management L. P.	801-54641	SEC	NO
119033	Los Angeles Capital Management & Equity Research Inc	549300DZCL1LRBNVU327	SEC	NO
111298	Arrowstreet Capital Limited Partnership	LO3UDTZUGORICVPFGQ53	SEC	NO
114537	Aegon USA Investment Management	4DJ1F67XTB552L0E3L78	SEC	N0

30.2 If yes, complete the following schedule:

1	2	3
		Book/Adjusted
CUSIP#	Name of Mutual Fund	Carrying Value
316146-10-9	Fid Inv Gr Bond	29,214
701769-40-8	Parnassus Equity IS	7,936
74256W-58-4	PIF MidCap Fund R6	41,408
378690-82-0	Glenmede Sm Cap E IS	207,493
315911-75-0	Fid 500 Index IPR	17,337
315911-72-7	Fid Intl Index IPR	7 , 175
411512-52-8	Harbor Cap App Ret	4,176
92646A-82-3	Victory Special Value I	6,389
315794-79-2	Fid Freedom 2015 K	179,114
	Fid Freedom 2020 K	199,580
315794-77-6	Fid Freedom 2025 K	168, 138
	Fid Freedom 2030 K	18,655
	Fid Freedom 2035 K	95,013
31618H-36-6	Fid Intl Cap Appr K6	3,927
47803W-70-3		
464287-20-0	ISHARES CORE S&P ETF	
46429B-67-1	ISHARES MSCI CHINA ETF	1.003.010
464287-23-4	ISHARES MSCI EMERGING MARKETS ETF	713.280
922042-87-4	VANGUARD EUROPEAN STOCK INDEX FUND	
922042-85-8	VANGUARD EMERGING MARKETS STOCK IN	1.395.181
921943-85-8	VANGUARD DEVELOPED MARKETS INDEX F	15.360.583
30.2999 - Total		117,561,547

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation
Fid Inv Gr Bond (FBNDX)	Corporate	11,104	12/31/2022

1	2	3 Amount of Mutual Fund's Book/Adjusted Carrying Value	4
Name of Mutual Fund (from above table)	Name of Significant Holding of the Mutual Fund	Attributable to the Holding	Date of Valuation
Fid Inv Gr Bond (FBNDX)	GNMA and Other Mtg backed		12/31/2022
Fid Inv Gr Bond (FBNDX)	Treasury Notes/Bonds		12/31/2022 12/31/2022
Fid Inv Gr Bond (FBNDX)	Asset backed securities		12/31/2022
Glenmede SMCAP EQ IS (GTCSX)	Hostess Brands Inc. CI A		12/31/2022
Glenmede SMCAP EQ IS (GTCSX)	Matador Resources Co		12/31/2022 12/31/2022
Glenmede SMCAP EQ IS (GTCSX)	F.N.B. Corp	3,756	12/31/2022
Glenmede SMCAP EQ IS (GTCSX)	AMN Healthcare Services Inc	3,673	12/31/2022
Fid International Capital Appreciation K6 Fund (FAPCX) Fid International Capital Appreciation K6 Fund (FAPCX)	Taiwan Semiconductor Mfg Co Lt		12/31/2022 12/31/2022
Fid International Capital Appreciation K6 Fund (FAPCX)	Nestle S.A		12/31/2022
Fid International Capital Appreciation K6 Fund (FAPCX)	ASML Holdings NV	107	12/31/2022
Fid International Capital Appreciation K6 Fund (FAPCX)	AstraZeneca PLC		12/31/2022
Fid International Index IPR (FSPSX)	Nestle S.A		12/31/2022 12/31/2022
Fid International Index IPR (FSPSX)	Roche Holding AG		12/31/2022
Fid International Index IPR (FSPSX)	Shell PLC A		12/31/2022
Fid International Index IPR (FSPSX)PIF MidCap Fund R6 (PMAQX)	LVMH Moet Hennessy Luis Vuitton		12/31/2022 12/31/2022
PIF MidCap Fund R6 (PMAQX)	TransDigm Group Inc		12/31/2022
PIF MidCap Fund R6 (PMAQX)	O'Reilly Automotive Inc	1,934	12/31/2022
PIF MidCap Fund R6 (PMAQX)	Costar Group Inc		12/31/2022
PIF MidCap Fund R6 (PMAQX) Harbor Cap App Ret (HACAX)	Copart Inc.		12/31/2022 12/31/2022
Harbor Cap App Ret (HACAX)	Apple Inc	299	12/31/2022
Harbor Cap App Ret (HACAX)	Amazon.com Inc		12/31/2022
Harbor Cap App Ret (HACAX)	Microsoft CorpEli Lilly & Co		12/31/2022 12/31/2022
Fid 500 Index IPR (FXAIX)	Apple Inc		12/31/2022
Fid 500 Index IPR (FXAIX)	Microsoft Corp	960	12/31/2022
Fid 500 Index IPR (FXAIX)Fid 500 Index IPR (FXAIX)	Amazon.com Inc		12/31/2022 12/31/2022
Fid 500 Index IPR (FXAIX)	Berkshire Hathaway Inc. CI B		12/31/2022
Fid Freedom 2015 K (FFVFX)	Fidelity Series Investment Grade Bond Fund	54,773	12/31/2022
Fid Freedom 2015 K (FFVFX)	Fidelity Series Emerging Markets Fund Fidelity Series 0-5 Year Inflation Protected Bond		12/31/2022
	Index Fund		12/31/2022
	Fidelity Series Long-Term Treasury Bond Index Fund		
Fid Freedom 2015 K (FFVFX)Fid Freedom 2020 K (FFFDX)	Fidelity Series Investment Grade Bond Fund	/,541 53 707	12/31/2022 12/31/2022
Fid Freedom 2020 K (FFFDX)	Fidelity Series Emerging Markets Fund Fidelity Series 5+ year Inflation protected Bond	18,282	12/31/2022
Fid Freedom 2020 K (FFFDX)Fid Freedom 2020 K (FFFDX)	Index FundFidelity Series International Value Fund	9 081	12/31/2022 12/31/2022
Fid Freedom 2020 K (FFFDX)	Fidelity Series International Growth Fund	9,001	12/31/2022
Fid Freedom 2025 K (FFTWX)Fid Freedom 2025 K (FFTWX)	Fidelity Series Investment Grade Bond Fund Fidelity Series Emerging Markets Fund	39,344	12/31/2022 12/31/2022
Fid Freedom 2025 K (FFTWX)	Fidelity Series 5+ year Inflation protected Bond Index Fund	12,745	12/31/2022
Fid Freedom 2025 K (FFTWX)	Fidelity Series International Value Fund	8,592	12/31/2022
Fid Freedom 2025 K (FFTWX)	Fidelity Series International Growth Fund Fidelity Series Investment Grade Bond Fund	3 852	12/31/2022 12/31/2022
	Fidelity Series Emerging Markets Fund	1,972	12/31/2022
Fid Freedom 2030 K (FSNQX)	Fidelity Series International Value Fund	1,052	12/31/2022
Fid Freedom 2030 K (FSNQX)Fid Freedom 2030 K (FSNQX)	Fidelity Series International Growth FundFidelity Series Overseas Fund		12/31/2022
Fid Freedom 2035 K (FSTHX)	Fidelity Series Emerging Markets Fund	1,383	12/31/2022
Fid Freedom 2035 K (FFTHX)	Fidelity Series Investment Grade Bond Fund	11,193	12/31/2022
Fid Freedom 2035 K (FFTHX)	Fidelity Series Growth Company Fund	6,594	12/31/2022
Fid Freedom 2035 K (FFTHX)	Fidelity Series Growth & Income Fund Fidelity Series International Value Fund		12/31/2022 12/31/2022
Parnassus Equity IS (PRILX)	Microsoft Corp	526	12/31/2022
Parnassus Equity IS (PRILX)	Alphabet Inc CI A	419	12/31/2022
Parnassus Equity IS (PRILX)	Fiserv Inc		12/31/2022 12/31/2022
Parnassus Equity IS (PRILX)	Mastercard Inc.	276	12/31/2022
Victory Special Value (SSVSX)	Apple Inc	367	12/31/2022
Victory Special Value (SSVSX)	Microsoft Corp	302	12/31/2022
Victory Special Value (SSVSX)	SPDR S&P 500 ETF Trust		12/31/2022
Victory Special Value (SSVSX)	UnitedHealth Group Inc.	138	12/31/2022
John Hancock Disciplined Value Mid Cap fund (JVMRX)  John Hancock Disciplined Value Mid Cap fund (JVMRX)	Ameriprise Financial Inc		12/31/2022
John Hancock Disciplined Value Mid Cap fund (JVMRX)	AutoZone Inc		
John Hancock Disciplined Value Mid Cap fund (JVMRX)	CenterPoint Energy Inc.	28	12/31/2022
John Hancock Disciplined Value Mid Cap fund (JVMRX)	Ametek Inc.		
iShares Core S&P 500 ETFiShares Core S&P 500 ETF	Apple Inc		12/31/2022 12/31/2022
iShares Core S&P 500 ETF	Amazon.com Inc		12/31/2022
iShares Core S&P 500 ETF	Berkshire Hathaway Inc. CI B	1,556,787	12/31/2022
iShares Core S&P 500 ETF	Alphabet Inc Class A	1,475,798	12/31/2022
iShares MSCI China ETFiShares MSCI China ETF	Tencent Holdings Ltd	130,692 80 140	12/31/2022 12/31/2022
iShares MSCI China ETF	Meituan	48,345	12/31/2022
iShares MSCI China ETF	JD.com Class A Inc	29,789	12/31/2022
iShares MSCI China ETFiShares MSCI Emerging Markets ETF	China Construction Bank Corp Taiwan Semiconductor Mfg Co Lt	29,488	12/31/2022
iShares MSCI Emerging Markets ETF	Tencent Holdings Ltd	30,100	12/31/2022
iShares MSCI Emerging Markets ETF	Samsung Electronics Ltd	23,467	12/31/2022

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation
iShares MSCI Emerging Markets ETF	Alibaba Group Holding Ltd		12/31/2022
iShares MSCI Emerging Markets ETF	Meituan		12/31/2022
FTSE Europe ETF	Nestle S.A.	242,627	12/31/2022
FTSE Europe ETF	Roche Holding AG	172,841	12/31/2022
FTSE Europe ETF	ASML Holdings NV	171,218	12/31/2022
FTSE Europe ETF			
FTSE Europe ETF	AstraZeneca PLC	155,801	12/31/2022
FTSE Emerging Markets ETF	Taiwan Semiconductor Mfg Co Lt	59,295	12/31/2022
FTSE Emerging Markets ETF	Tencent Holdings Ltd	51,482	12/31/2022
FTSE Emerging Markets ETF	Alibaba Group Holding Ltd	33,484	12/31/2022
FTSE Emerging Markets ETF	Reliance Industries Ltd	20,928	12/31/2022
FTSE Emerging Markets ETF	Meituan Dianping Class B	18,416	12/31/2022
FTSE Developed Markets ETF	Nestle S.A.	239,625	12/31/2022
FTSE Developed Markets ETF	ASML Holdings NV	168,966	12/31/2022
FTSE Developed Markets ETF	Roche Holding AG	167,430	12/31/2022
FTSE Developed Markets ETF			12/31/2022
FTSE Developed Markets ETF	Novo Nordisk A/S Class B	162,822	12/31/2022

#### **GENERAL INTERROGATORIES**

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	1,399,817,104		(91,424,197)
31.2 Preferred stocks	0		0
31.3 Totals	1,399,817,104	1,308,392,907	(91,424,197)

31.4	Describe the sources or methods utilized in determining the fair values:				
	Custodians and Refinitiv (formerly Thomson Reuters) are the sources for fair values				
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes [ ]	Χ]	No [	]
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes [ ]	Х ]	No [	]
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:				
33.1	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes [ ]	Х]	No [	]
33.2	If no, list exceptions:				
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:  a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.  b. Issuer or obligor is current on all contracted interest and principal payments.  c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.				
	Has the reporting entity self-designated 5GI securities?	Yes [	]	No [ )	( )
35.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:  a. The security was purchased prior to January 1, 2018.  b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.  c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.  d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.				
	Has the reporting entity self-designated PLGI securities?	Yes [	]	No [ )	( )
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:  a. The shares were purchased prior to January 1, 2019.  b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.  c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.  d. The fund only or predominantly holds bonds in its portfolio.  e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.  f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.  Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Yes [	1	No. [ \	v 1
	Has the reporting entity assigned FE to Schedule BA hornegistered private runds that complied with the above criteria?	res [	1	NO [ /	۸ ]
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:  a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.  b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.  c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.  d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments.				
	Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?  Yes [	1 No [	X 1	N/A	[

38.1	Does the reporting entity directly hold cryptocurrencies?			Yes [	] N	lo [ X ]
38.2	If the response to 38.1 is yes, on what schedule are they reported?					
39.1	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiur	ms on policies?		Yes [	] N	lo [ X ]
39.2	39.21 Held directly				] N	0 [ ]
39.3	39.22 Immediately converted to  If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of premiu			Yes [	] N	0 [ ]
	Name of Cryptocurrency	2 Immediately Converted to USD, Directly Held, or Both	3 Accepted for Payment of Premiums			
40.4	OTHER			_		0.400.400
40.1	Amount of payments to trade associations, service organizations and statistical or rating burea.  List the name of the organization and the amount paid if any such payment represented 25% service organizations and statistical or rating bureaus during the period covered by this statem	or more of the total payme				3,106,138
	1		2			
	American Association of Health Plans		2 , 170 , 423			
41.1	Amount of payments for legal expenses, if any?			\$		
41.2	List the name of the firm and the amount paid if any such payment represented 25% or more during the period covered by this statement.	of the total payments for le	gal expenses			
	1 Name		2 unt Paid			
42.1	Amount of payments for expenditures in connection with matters before legislative bodies, offi	•		\$		
42.2	List the name of the firm and the amount paid if any such payment represented 25% or more connection with matters before legislative bodies, officers, or departments of government during					
	1 Name	Amou	2 unt Paid			

# **GENERAL INTERROGATORIES**

#### PART 2 - HEALTH INTERROGATORIES

1.1 1.2 1.3	Does the reporting entity have any direct Medicare Supplement Insurance in force If yes, indicate premium earned on U.S. business only		\$	28,48	] 11,252 0
	1.31 Reason for excluding				
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien	not included in Item (1.2) above		20,05	0
1.5	Indicate total incurred claims on all Medicare Supplement Insurance.		. \$	20,00	5,003
1.6	Individual policies:	Most current three years:	•		٥
		1.61 Total premium earned			
		1.63 Number of covered lives			0
		All years prior to most current three years:		00.40	4 050
		1.64 Total premium earned			
		1.65 Total incurred claims			
		1.00 Number of 6070160 m/66			0,0.2
1.7	Group policies:	Most current three years:			•
		1.71 Total premium earned			
		1.72 Total incurred claims			
		1.73 Number of covered lives			0
		All years prior to most current three years:			
		1.74 Total premium earned	. \$		0
		1.75 Total incurred claims	\$		0
		1.76 Number of covered lives			0
2.	Health Test:				
۷.	Troutti 165t.	1 2			
		Current Year Prior Year			
	2.1 Premium Numerator				
	2.2 Premium Denominator				
	2.3 Premium Ratio (2.1/2.2)	1.0001.000			
	2.4 Reserve Numerator				
	2.5 Reserve Denominator	600,999,223			
	2.6 Reserve Ratio (2.4/2.5)	1.0001.000			
3.1	Has the reporting entity received any endowment or gift from contracting hospita returned when, as and if the earnings of the reporting entity permits?		Yes [ ]	No [ )	Х ]
4.1	Have copies of all agreements stating the period and nature of hospitals', physic dependents been filed with the appropriate regulatory agency?	cians', and dentists' care offered to subscribers and	Yes [ X ]	No [	]
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these	se agreements include additional benefits offered?	Yes [ ]	No [ ]	Х]
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [ X ]	No [	]
5.2	If no, explain:				
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical	\$	<b>ረ</b> በ	n nnn
0.0		5.32 Medical Only			
		5.33 Medicare Supplement	Φ		
		5.34 Dental & Vision	.ψ ¢		
		5.35 Other Limited Benefit Plan			
		5.36 Other			
6.	Describe arrangement which the reporting entity may have to protect subscribers hold harmless provisions, conversion privileges with other carriers, agreements agreements:  Hold harmless provisions are included in contracts with providers. BCN has stop insovency clause. In addition, BCN holds a state-mandated cash deposit and B	with providers to continue rendering services, and any other p-loss coverage through an affiliate which includes an			
7.1	Does the reporting entity set up its claim liability for provider services on a service	ce date basis?	Yes [ X ]	No [	]
7.2	If no, give details				
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year 8.2 Number of providers at end of reporting year .			
9.1	Does the reporting entity have business subject to premium rate guarantees?		Yes [ X ]	No [	]
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months 9.22 Business with rate guarantees over 36 months			

10.1	Does the reporting entity have Incentive Pool, Withh	Yes [ X ]	No [ ]							
10.2	If yes:				ount payable bonus					
					ount payable withh					
			1	0.24 Amount actua	ally paid for year wit	hholds	\$	8,293,991		
11.1	Is the reporting entity organized as:									
					al Group/Staff Mode			No [X]		
					dual Practice Asso	, ,, ,	Yes [ X ]			
				11.14 A Mixed	Model (combination	ı of above)?	Yes [ ]	No [X]		
44.0	le the annualization and the collection of the Collection of Minimum of	Oit-1 1 O	lua Danidarananta	0			V 2 0 0 V	No I 1		
11.2 11.3	Is the reporting entity subject to Statutory Minimum of the state requiring such mi						Yes [ X ]	No [ ] Michigan		
11.4	If yes, show the amount required.		-					311,370,336		
11.5	Is this amount included as part of a contingency res						Yes [ ]			
11.6		0.70 0.00								
	The greater of 4% of subscription revenue \$4,185,2 \$155,685,168= \$311,370,336.									
12.	List service areas in which reporting entity is license	d to operate:								
			1 Name of Service	e Area						
	Michigan									
	· ·									
13.1	Do you act as a custodian for health savings accour	nts?					Yes [ ]	No [ X ]		
13.2	If yes, please provide the amount of custodial funds	held as of the re	porting date				\$			
13.3	Do you act as an administrator for health savings ac	counts?					Yes [ ]	No [ X ]		
13.4	If yes, please provide the balance of funds administe	ered as of the re	porting date				\$			
14.1	Are any of the captive affiliates reported on Schedul	e S. Part 3. auth	orized reinsurers?	,		Yes [	] No [ X	1 N/A [		
	If the answer to 14.1 is yes, please provide the follow					, 55	1 [	1		
	1	2	3	4	Assets	Supporting Reserve	e Credit			
		NAIC	Dominilian	Doggra	5	-6	7			
	Company Name	Company Code	Domiciliary Jurisdiction	Reserve Credit	Letters of Credit	Trust Agreements	Other			
	Company name			0.001		7 igreemente	Othor			
15.	Provide the following for individual ordinary life insurceded):	rance* policies (l	J.S. business only		ar (prior to reinsura			<del></del>		
		ns								
					Number of Covered					
	*Ordinary Life Insurance Includes  Term(whether full underwriting, limited underwriting, jet issue, "short form app")									
	Term(whether full und Whole Life (whether f					_				
	Variable Life (with or			ig, jet issue, snor	поппарр )	$\dashv$				
	Universal Life (with or		, ,							
	Variable Universal Life			antee)	·					
16.	Is the reporting entity licensed or chartered, register	ed, qualified, elig	gible or writing bus	siness in at least tw	o states?		Yes [ ] No	[ X ]		
16.1	If no, does the reporting entity assume reinsurance I domicile of the reporting entity?						Yes [ ] No	[ X ]		

#### **FIVE-YEAR HISTORICAL DATA**

	1146	1 2022	2 2021	3 2020	4 2019	5 2018
	Polence Cheet (Posses 2 and 2)	2022	2021	2020	2019	2016
4	Balance Sheet (Pages 2 and 3)  Total admitted assets (Page 2, Line 28)	2 672 166 704	2 701 006 092	2 972 204 246	2 640 220 447	2 402 750 104
1.	· -					
2.	Total liabilities (Page 3, Line 24)					
3.	Statutory minimum capital and surplus requirement .					
4.	Total capital and surplus (Page 3, Line 33)	1,751,451,782	1,/91,3/9,/25	1,908,517,681	1,728,923,443	1,609,353,975
	Income Statement (Page 4)					
5.	Total revenues (Line 8)					
6.	Total medical and hospital expenses (Line 18)					
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)	3, 178,971	122,251,406		90,000,470	45,082,438
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)	(36, 179, 252)	(98,095,077)	132,354,775	74,746,591	250,612,170
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	(35,689,097)	(145,805,315)	102,566,518	111,917,126	280,665,011
	Risk-Based Capital Analysis					
14.	Total adjusted capital	1,751,451,782	1,791,379,725	1,908,517,681	1,728,923,443	1,609,353,975
15.	Authorized control level risk-based capital	155,685,168	153,026,423	137, 128,942	142,022,781	133,863,196
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7) .	663,057	669,179	704,385	745,471	738,743
17.	Total members months (Column 6, Line 7)	7,961,550	8,092,569	8,663,457	8,928,617	8,912,663
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)					
20.	Cost containment expenses					
21.	Other claims adjustment expenses	2.0	1.9	2.1	1.8	1.8
22.	Total underwriting deductions (Line 23)	101.0	105.6	98.9	100.4	95 . 1
23.	Total underwriting gain (loss) (Line 24)	(1.0)	(5.6)	1.1	(0.4)	4.9
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	481,919,359	503,573,186	457,535,254	460,938,186	370,506,869
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	364,809,223	398,848,667	408,416,272	420,826,747	349, 161,914
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)				0	
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)		0	0	0	
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31					
	Total investment in parent included in Lines 26 to	,, -30				

### SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS


Allocated by States and Territories

		Allocated by States and Territories  1 Direct Business Only										
			Active	2	3	4	5	6 Federal Employees Health Benefits	7 Life and Annuity	8 Property/	9 Total	10
	States, etc.		Status (a)	Accident and Health Premiums	Medicare Title XVIII	Medicaid Title XIX	CHIP Title XXI	Program Premiums	Premiums & Other Considerations	Property/ Casualty Premiums	Total Columns 2 Through 8	Deposit-Type Contracts
1.	Alabama		N								0	
2.		AK	N								0	
3.	Arizona	AZ	N								0	
4.		AR	N								0	
5.	California	CA	N								0	
6.			N								0	
7.	Connecticut	CT	N								0	
8.	Delaware	DE	N								0	
9.		DC	N								0	
			N								0	
11.	Georgia		N								0	
	Hawaii		N								0	
	Idaho	ID	N								0	
		IL	N								0	
15.	Indiana	IN	N								0	
16.		IA	N								0	
17.		KS	N								0	
18.	-		N								0	
19.	Louisiana		N								0	
20.		ME	N								0	
21.	-	MD	N								0	
22.	Massachusetts	MA	N								0	
23.	=	MI		2,878,099,173	1, 190, 471, 122			116,653,251			4,185,223,546	
24.	Minnesota		N								0	
25.	Mississippi	MS	N								0	
26.	Missouri	MO	N								0	
		MT	N								0	
		NE	N								0	
29.	Nevada		N								0	
30.	•		N								0	
31.	New Jersey		N								0	
32.	New Mexico	NM	N								0	
33.			N								0	
34.	North Carolina	NC	N								0	
35.	North Dakota	ND	N								0	
36.	Ohio	ОН	N								0	
37.	Oklahoma	OK	N								0	
38.	Oregon	OR	N								0	
39.	Pennsylvania	PA	N								0	
40.	Rhode Island	RI	N								0	
41.	South Carolina	SC	N								0	
42.	South Dakota	SD	N								0	
43.	Tennessee	TN	N								0	
44.	Texas	TX	N								0	
45.	Utah	UT	N								0	
46.	Vermont		N								0	
	Virginia		N								0	
48.	Washington		N								0	
49.	West Virginia		N								0	
50.			N								0	
	Wyoming		N								0	
52.	American Samoa	-	N								0	
		GU	N								0	
54.	Puerto Rico		N								0	
	U.S. Virgin Islands	VI	N								0	
56.	Northern Mariana		<b>A</b> 1		1			1			_	
		MP	N								0	•••••
57.		CAN	N								0	
58.	Aggregate Other Aliens	ОТ	XXX	0	0	0	0	0	0	0	0	0
59.	Subtotal			2,878,099,173		0		116,653,251			4, 185, 223, 546	
60.	Reporting Entity Contributions for En	nployee	XXX		1, 100,47 1, 122						4, 165,225,546	
61	Benefit Plans Totals (Direct Busine			2,878,099,173	1 190 471 122	0	0	116,653,251	0	Λ	4, 185, 223, 546	0
01.	DETAILS OF WRITE		<b>^^</b>	2,010,033,113	1, 100,4/1, 122	J	0	110,000,201	U	- 0	7, 103,223,340	U
58001.			<b>VVV</b>		1			1				
58001.			XXX									
58003.			XXX							•		
	Summary of remainir write-ins for Line 58 f	ng From										
58999.	overflow page Totals (Lines 58001 t 58003 plus 58998)(Li	through	XXX	0	0	0	0	0	0		0	0
(a) Active	above) Status Counts:		XXX	0	0	0	0	0	0	0	0	0

<sup>(</sup>b) Explanation of basis of allocation by states, premiums by state, etc. By Situs of Contract




#### **SUBSIDIARY & AFFILIATE ORGANIZATION CHART**



- BCBSM owns an 80% stake of LifeSecure Holdings Corporation with the remaining 20% owned by BCS Financial Corporation.
- 2 Michigan Medicaid Holdings Company owns a 50% stake of Blue Cross Complete of Michigan LLC. Remaining 50% stake is owned by AmeriHealth Caritas Health Plan.
- 3 See pg. 2 for additional subsidiaries.
- 4 See pg. 4 for additional affiliates.
- 5 See pg. 5 for affiliated companies.
- 6 BCBSM owns a 20% stake of Evio Pharmacy Solutions, LLC.
- 7 BCBSM owns a 9.99% stake of InnovateRx LLC.
- Innovate Rx LLC does not have an equity ownership in Civica Outpatient Subsidiary, LLC, which is a non-profit company. However, Innovate Rx LLC does have the right to appoint five managers to Civica Outpatient Subsidiary, LLC's board of managers which can range from 6 to 10 managers.
- managers.
  9 See pg. 6 for additional subsidiaries







<sup>1</sup> See page 3 for additional subsidiaries and affiliates.

<sup>2</sup> Emergient, Inc. owns a 51% stake in Vermont Blue Advantage LLC

<sup>3</sup> Emergient, Inc. owns a 51% stake in Wellmark Advantage Holdings, LLC

<sup>4</sup> Emergient, Inc. owns a 51% stake in NextBlue, LLC.






All entities that do not reflect a particular state name or abbreviation are domiciled in Michigan.




#### **SUBSIDIARY & AFFILIATE ORGANIZATION CHART**



<sup>1</sup> Blue Cross Blue Shield of Michigan owns 10.1% of BCS Financial Corporation Accident Fund Insurance Company of America owns 3,58% of BCS Financial Corporation.

<sup>2</sup> BCS Financial owns a 20% stake in LifeSecure Holdings Corporation with the remaining 80% owned by BCBSM.

<sup>3</sup> BCS Financial Corporation owns 50% of Ancilyze Technologies LLC.



GioStream Inc. 401(k) Plan & Trust EIN: 34-2032238

<sup>1</sup> GloStream Inc. owns a 50% stake in One Team Care, LLC.

TRIARQ Health, LLC owns a 99.99% stake in TRIARQ Health LLP.
 TRIARQ Health, LLC owns a 99.99% stake in TRIARQ Health Alliance of Florida.
 TRIARQ Health, LLC owns a 90% stake in TRIARQ Health Alliance of Michigan.
 TRIARQ Health, LLC owns a 98% stake in TRIARQ Health Alliance of Michigan.
 Care Transformation Holding Company owns a 19.9% stake in Honest Medical of Michigan LLC

# NONE